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Summary 
 
Life-threatening Staphylococcus aureus infections and the 
emergence of antibiotic-resistant strains make vaccination a major medical 
need. Novartis Vaccines developed a vaccine candidate (Combo) that 
consists of HlaH35L, a non-toxic mutant of the α-toxin, EsxAB, a fusion of the 
secreted factors EsxA and EsxB, and of two surface proteins, FhuD2 and 
Sur2. Combo±alum has shown efficacy in pre-clinical mouse models and 
has recently been tested in a human phase I clinical trial.  
To improve this vaccine further, Combo antigens were formulated 
with alum/SMIP-7.10 (alum-S-7), a novel adjuvant formulation composed of 
a Toll-like receptor 7 agonist small molecule adsorbed to a lum. We 
characterized the immune responses elicited by this novel formulation, and 
compared its efficacy to that induced by Combo±alum in a mouse model of 
S. aureus-induced peritonitis. 
Combo+alum-S-7 showed increased efficacy than Combo+alum, 
with 75%, respectively 40%, of mice surviving a lethal challenge. Compared 
to Combo+alum, Combo+alum-S-7 induced higher vaccine-specific antibody 
titers, and polarized CD4+ T-cell responses towards Th1 and Th17 effectors 
(IFN-  or IL-17 production, respectively). In vivo depletion of CD4+ effector T 
cells in mice vaccinated with Combo+alum-S-7 reduced the efficacy of this 
vaccine by 20%. The residual protection was likely due to Combo-specific 
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antibodies since passive transfer of sera from mice immunized with 
Combo+alum-S-7 to naïve mice resulted in 30% of survival. The 
requirement of B cells/antibodies to confer protection against S. aureus in 
the peritonitis model by Combo vaccination was confirmed by the death of 
96% of B-cell ko JH mice vaccinated with Combo+alum/S-7 or Combo+alum. 
In vivo neutralization of IL-17A, either alone or together with IFN-, but not of 
IFN- alone, increased bacterial loads in kidneys of mice immunized with 
Combo+alum-S-7 as did the depletion of CD4+ effector T cells.  
Overall these data show that adding SMIP-7.10 to Combo+alum 
increases the efficacy of this candidate vaccine through combined antibody 
and Th17 responses in an animal model of S. aureus infection. 
 
  
 
 
Riassunto 
 
L'emergenza di ceppi di Staphylococcus aureus resistenti  agli 
antibiotici  rende i l trattamento dei pazienti più difficile e, al tempo stesso, 
più urgente la necessità di un vaccino. Novartis Vaccines ha sviluppato un 
candidato vaccino (Combo) che consiste di: HlaH35L, un mutante atossico 
della tossina-α; EsxAB, fusione delle due proteine secrete EsxA e EsxB; 
FhuD2 e Sur2, due proteine di superficie. È stato dimostrato che 
Combo±alum è efficace in modelli animali preclinici ed il vaccino è stato 
recentemente testato nella fase I di un clinical trial.  
Al fine di migliorare ulteriormente il vaccino, gli antigeni di Combo 
sono stati formulati  con alum/SMIP-7.10 (alum-S-7), un nuovo adiuvante 
composto da una small molecule, agonista del Toll-like receptor 7, 
adsorbita all’alum. Abbiamo caratterizzato le risposte immunitarie indotte da 
questa nuova formulazione e abbiamo confrontato la sua efficacia con 
quella di Combo±alum in un modello murino di peritonite indotta da             
S. aureus. 
Combo+alum-S-7 ha dimostrato un’efficacia superiore a quella di  
Combo+alum, con il 75% dei topi, rispetto al 40%, che sopravvivevano 
all’infezione letale. In confronto a Combo+alum, Combo+alum-S-7 ha 
indotto titoli anticorpali specifici per il vaccino più elevati e ha polarizzato le 
riposte T CD4+ verso  risposte di tipo Th1 e Th17 effettrici (produzione di 
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IFN- o IL-17, rispettivamente). La deplezione in vivo delle cellule T CD4+ 
effettrici nei topi vaccinati con Combo+alum-S-7 ha ridotto l’efficacia del 
vaccino del 20%. La protezione residua era verosimilmente dovuta agli 
anticorpi specifici per i l vaccino: un passive transfer di sieri di topi 
immunizzati con Combo+alum-S-7 in topi naïve ha infatti conferito una 
protezione del 30%. La necessità della presenza di cellule B/anticorpi per 
proteggere i topi vaccinati con Combo dall’infezione con S. aureus nel 
modello di peritonite è stata confermata dalla morte del 96% dei topi JH 
(deficienti delle cellule B) vaccinati con Combo+alum/S-7 o Combo+alum. 
La neutralizzazione  in vivo di IL-17A, sia da sola che in combinazione con 
IFN-, ma non del solo IFN-, ha aumentato la carica batterica nei reni dei 
topo immunizzati con Combo+alum-S-7, come successo in seguito a 
deplezione delle cellule T CD4+ effettrici.  
Nell’insieme, questi dati dimostrano che l’aggiunta dello SMIP-7.10 
al vaccino Combo+alum ne aumenta l’efficacia in un modello animale di 
infezione con S. aureus attraverso l’induzione di anticorpi e risposte Th17. 
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Chapter 1 
Introduction 
 
1.1 Staphylococcus aureus 
Staphylococci are gram-positive bacteria belonging to the family of 
Micrococcaceae that form grape-like clusters on Gram’s stain (Figure 1.1). 
These organisms are catalase-positive, non-motile, aerobic, and facultative 
anaerobic. They are capable of prolonged survival on environmental 
surfaces in varying conditions. S. aureus is distinguished from other 
staphylococcal species on the basis of the gold pigmentation of colonies 
and positive results of coagulase, mannitol fermentation, and 
deoxyribonuclease tests [1]. 
 
1.1.A S. aureus structure and components 
S. aureus has a nuclear body surrounded by a plasma membrane 
composed primarily of proteins and phospholipids (about 3:1). The cell wall 
is 50% peptidoglycan (PGN), confers the characteristic cell shape and 
provides the cell with mechanical protection.  Most staphylococci present a 
microcapsule [2]. 
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Figure 1.1 Gram’s stain of S. aureus. Leukocytes in a sputum sample (Gram’s 
Stain, 1,000x) [3]. 
 
1.1.A.1 Genome 
The staphylococcal genome consists of a ≈2 ,800 bp circular 
DNA, with prophages, plasmids, and transposons. Virulence and resistance 
to antibiotics are regulated by genes found on the chromosome, as well as 
on extra-chromosomal elements [3]. Comparative analysis revealed that 
most regions of the staphylococcal genome are well conserved, whereas 
several large sequence blocks display high variability. The overall 
combination of variable sequence elements and the encoded spectrum of 
virulence properties varies from strain to strain and appears to be reflective 
of the overall large spectrum of clinical disease manifestations in humans [4].  
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1.1.A.2 Cell wall 
The staphylococcal cell wall is made of a thick layer of PGN, 
which consists of alternating polysaccharide subunits of                               
N-acetylglucosamine and N-acetylmuramic acid with 1,4-β linkages. The 
PGN chains are cross-linked by tetrapeptide chains bound to                     
N-acetylmuramic acid and by a pentaglycine bridge specific for S. aureus. In 
this layer, there are PGN-anchored (teichoic acid) and membrane-anchored 
(e.g., lipoteichoic acid) glycopolymers as well as lipoproteins and covalently 
and non-covalently attached proteins [5]. The best-characterized pathogen-
associated molecular patterns (PAMPs) of S. aureus are components of its 
cell wall or their fragments (reviewed in [6]). 
 
1.1.A.3 Capsule 
The capsule is composed by polysaccharides: 11 types of 
microcapsular polysaccharide serotypes have been identified. Serotypes 5 
and 8 account for 75% of human infections; most methicillin-resistant          
S. aureus isolates are type 5. The chemical composition of only 4 of these 
antiphagocytic polysaccharides, including types 5 and 8, has been 
determined [7]. 
 
1.1.A.4 Surface proteins 
Many staphylococcal surface proteins are characterized by 
common features which are implicated in the proper secretion and 
attachment of these proteins to the cell surface and in the interaction with 
the host. These common features are a secretory signal sequence at the   
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N-terminal, positively charged amino acids that extend into the cytoplasm, a 
hydrophobic membrane-spanning domain, and a cell-wall–anchoring region, 
all at the C-terminal [8]. A ligand-binding domain at the N-terminal that is 
exposed on the surface of the bacterial cell enables some of these proteins 
to function as adhesins. Protein A is the prototype of these proteins and has 
anti-phagocytic properties due to its ability to bind the Fc portion of 
immunoglobulins. Several of these related proteins bind extracellular matrix 
molecules and play an important part in the ability of S. aureus to colonize 
host tissues [3]. 
 
1.1.A.5 Toxins 
Depending on the strain, S. aureus is capable of secreting 
several exotoxins, which can be categorized into 3 groups on the basis of 
their mechanism of action. Many of these toxins are associated with specific 
diseases. Cytotoxins, such as the α-toxin, also known as α-hemolysin (Hla), 
cause pore formation in mammalian cells and induce pro-inflammatory 
cytokine release. The consequent cellular damage may contribute to 
manifestations of the sepsis syndrome [9] [10]. The pyrogenic-toxin 
superantigens bind to major histocompatibility complex class II proteins, 
causing non-specific activation of T cells resulting in polyclonal T-cell 
activation and massive cytokine release [11] leading to the toxic shock 
syndrome and food poisoning [12]. The exfoliative toxins cause skin 
erythema and separation, as seen in the staphylococcal scalded skin 
syndrome. Their mechanism of action remains controversial. Panton 
Valentine leukocidin is a leukocytolytic toxin that has been epidemiologically 
associated with severe cutaneous infections [13]. 
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1.1.B S. aureus epidemiology and pathogenesis 
S. aureus is frequently part of the commensal flora found in the 
nose and on skin. Approximately 20% of individuals almost always carry 
one type of strain and are called persistent carriers. A large proportion of the 
population (≈60%) harbors S. aureus intermittently, and the strains change 
with varying frequency. Such persons are called intermittent carriers. Finally, 
a minority of people (≈20%) almost never carry S. aureus and are called 
non-carriers [14]. 
S. aureus is both a commensal organism and a pathogen. It is 
responsible for nosocomial and community-acquired infections that range 
from minor skin infections, such as pimples, impetigo, and scalded skin 
syndrome, to life-threatening diseases such as pneumonia, meningitis, 
osteomyelitis, endocarditis, and toxic shock syndrome. Infections of the 
blood can carry the bacteria to various deep tissues, including bones, joints, 
organs, and the respiratory system. S. aureus is a pluripotent pathogen, 
causing diseases through both toxin-mediated and non–toxin-mediated 
mechanisms [3]. 
More than 30 staphylococcal species are pathogenic: among them 
S. aureus is the most virulent one. The “other” staphylococci are collectively 
designated coagulase-negative staphylococci (CoNS), as only S. aureus 
produces coagulase, a surface enzyme that converts fibrinogen to fibrin. 
CoNS are considerably less virulent than S. aureus but remain important 
pathogens in infections associated with prosthetic devices [15]. 
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1.2 The immune system 
The word immunity means protection against foreign substances 
that are not normally present in the organism or are not part of it. The cells 
and molecules responsible for immunity constitute the immune system, and 
their collective and coordinated response to the introduction of foreign 
substances is called the immune response. The key to a healthy immune 
system is its remarkable ability to distinguish between the body’s own cells, 
recognized as “self,” and foreign cells, or “non-self.” The body’s immune 
defenses normally coexist peacefully with cells that carry distinctive “self” 
marker molecules. But when immune defenders encounter foreign cells or 
organisms carrying non-self markers they quickly launch an attack. Anything 
that can trigger this immune response is called an antigen (Ag). Ag 
(ANTIbody GENerator) was originally defined as a structural molecule that 
binds specifically to the antibody (Ab), but the term now also refers to any 
molecule or molecular fragment that can be recognized by highly variable 
Ag receptors on B cells (BCR) or T cells (TCR) of the adaptive immune 
system. An Ag can be a microbe, such as a bacterium or a virus, or a part of 
a microbe such as a bacterial protein.  
In abnormal situations, the immune system can mistake self for non-
self and launch an attack against the body’s own cells or tissues. The result 
is an auto-immune disease. Some forms of arthritis and diabetes are auto -
immune diseases. In other cases, the immune system responds to a 
seemingly harmless foreign substance such as ragweed pollen. The result 
is allergy, and this kind of Ag is called an allergen.   
In order to escape host’s immunity, microbes tend to evolve 
introducing a greater variability in their phenotype. Therefore different and 
complex mechanisms are necessary to face microbial invasion, and indeed 
the immune system is composed of different cell types and an enormous 
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number of molecular mediators. Defense against microbes is mediated by 
different types of immune responses: innate and adaptive.  
Innate immunity (also called natural or native immunity) provides the 
early line of defense against microbes [16]. This type of response is very 
fast, highly efficient and addresses broad classes of pathogens in an       
Ag–non-specific manner.  
The principal components of innate immunity are physical and 
chemical barriers, phagocytic cells (neutrophils, N and macrophages, M), 
natural killer (NK) cells, blood proteins (including members of the 
complement system and other mediators of inflammation), and proteins 
called chemokines and cytokines that regulate and coordinate many of the 
activities of the cells of the immune system. When a pathogen enters in the 
body for the first time, it is recognized and is  phagocytosed by different 
immune cells like M, N, monocytes (Mo), and dendritic cells (DC), which 
produce inflammatory cytokines and chemokines that attract more 
specialized immune cells to the site of infection. The mechanisms of innate 
immunity are specific for broad classes of microbes and may not distinguish 
fine differences between foreign substances. 
Adaptive immunity is induced by exposure to infectious agents and 
increases in magnitude and defensive capabilities with each successive 
exposure to the same microbe. This form of immunity develops as a 
response to a particular infection and adapts to it, and therefore is called 
adaptive immunity. The defining characteristics of adaptive immunity are 
specificity, and ability to “remember” and respond more vigorously to 
repeated exposures to the same microbe. Because the adaptive immune 
system has an extraordinary capacity to distinguish between different, even 
closely related, microbes and molecules, it is also called specific immunity.  
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The main components of adaptive immunity are B and T 
lymphocytes and their secreted products, such as antibodies (Abs). B and T 
lymphocytes go through a long maturation and selection process during the 
first period of their life. At the end of this period, only functional B and T 
lymphocytes with a low affinity for self-Ag are selected. When these cells 
encounter the Ag for which they are specific, they undergo clonal expansion 
leading to a very specific immune response. The invading pathogen is 
eliminated through release of specific Abs and the action of effector T cells. 
Moreover, some of the Ag-specific B and T cells can differentiate into 
memory cells that can recognize immediately the same pathogen upon re-
encounter. As a result the memory immune response is faster and stronger 
[16]. 
 
1.3 Innate immunity 
The innate immunity constitutes the first line of defense against 
infection and in many cases is sufficient to eliminate the invading agent. In 
other cases it cannot cope with the infection, but it initiates the development 
of an adaptive immune response.  
Innate immune recognition of infectious agents is based on two 
main principles: the detection of PAMPs and aberrant localization of specific 
classes of molecules.  
PAMPs are microbial molecular structures that are evolutionarily 
conserved, and hence shared between different microbial species [17]. Most 
PAMPs are essential for microbial growth and survival of the 
microorganisms to which they belong, and therefore these molecular 
patterns are rarely modified by the microorganism as a mean to avoid innate 
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recognition [16] [17]. PAMPs include lipids, lipopeptides, polysaccharides 
and nucleic-acid structures that are broadly expressed by different groups of 
microorganisms. The cells of the innate immune system are able to 
recognize these molecular patterns by pattern recognition receptors (PRRs), 
which are innate immune receptors extremely conserved throughout 
evolution. 
The second principle in innate recognition is the presence of 
specific molecular structures in unusual intracellular compartments. Viruses, 
intracellular bacteria, and some parasites replicate inside the cells they 
infect. The innate immune system senses the presence of viruses through 
detection of viral glycoproteins at the cell surface, or viral nucleic acids in 
endosomes or in the cytoplasm. Some bacteria replicate inside eukaryotic 
host cells either in endosomes or in the cytoplasm. These bacteria activate 
the innate system through lipid components, cell wall products, and bacterial 
nucleic acids. These microbial molecules are recognized by specialized 
PRRs as non-self molecules due to their unusual intracellular localization, 
thus stimulating innate response.  
All the principal components of the innate immunity cooperate at the 
elimination or the attenuation of the infection.  
Epithelial barriers not only constitute a physical obstacle to the 
infection, but they also produce chemical substances that are microbicidal 
or that inhibit microbial growth, such as defensins that are peptides with a 
high bactericidal activity.  
Phagocytic cells, such as N, Mo, and M capture the microbe and 
kill it in the phagolysosomes through different mechanisms. M and N 
recognize pathogens by means of cell-surface receptors that can 
discriminate between the surface molecules displayed by pathogens and 
10                                                                                                                            CHAPTER 1 
 
those of the host. In many cases, binding of a pathogen to these cell-
surface receptors leads to phagocytosis, followed by the death of the 
pathogen inside the phagocyte. Phagocytosis is an active process in which 
the pathogen is first surrounded by the phagocyte membrane and then 
internalized in a membrane-enclosed vesicle, known as a phagosome or 
endocytic vacuole. The phagosome then becomes acidified upon fusion with 
one or more lysosomes. Lysosomes are membrane-enclosed granules that 
contain proteolitic enzymes and peptides that can attack the microbe. The 
phagosome fuses with one or more lysosomes to generate a 
phagolysosome in which the lysosomal contents are released to destroy the 
pathogen. Upon phagocytosis, M and N produce a variety of other toxic 
products that help kill the engulfed microorganism. The most important of 
these toxic products are the antimicrobial peptides and nitric oxide (NO), the 
superoxide anion, and hydrogen peroxide which are directly toxic to bacteria. 
NK cells are the effector cells of the innate immune response and 
are able to kill microbes by producing perforins or by enhancing the 
phagocytic activity of M. NK cells can recognize microbes and cells 
infected by viruses or intracellular bacteria in an Ag–non-specific manner. 
Finally, important components of innate immunity are soluble 
molecules, such as cytokines, chemokines, and plasma proteins that 
constitute the complement system. These molecules are produced by cells 
of the innate system and are active on cells of both the innate and adaptive 
immunity. Chemokines release favors the leukocyte mobility from the lymph 
nodes to the site of infection through the endothelial barriers. Cytokines 
promote the phagocytic ability of M and N, the cytotoxic activity of NK 
cells, and the differentiation and activation of T and B cells [16] [17] [18]. 
The complement proteins react with one another to opsonize pathogens and 
induce a series of inflammatory responses that help to fight infection.  
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The innate immunity, although characterized by non-specific and 
short-term responses, plays an important role in the initiation of the adaptive 
immunity.  
 
1.4 Adaptive immunity 
The adaptive response is divided into humoral response and cell-
mediated immune response. The main components of adaptive immunity 
are cells called B and T lymphocytes and their secreted products, such as 
Abs. These cells are responsible for exerting effector functions upon 
receiving signals from innate cells. B and T lymphocytes go through a long 
maturation and selection process during the first period of their life. B 
lymphocytes mature in the bone marrow and mount the humoral immune 
response, while T lymphocytes mature in the thymus and are responsible 
for the cell-mediated immune response. Mature B and T cells leave the 
bone marrow or the thymus, enter the bloodstream and migrate to the 
peripheral lymphoid organs. Circulating mature B and T cells that have not 
encountered their specific Ags are called naïve B and T cells, respectively.  
Mature B cells express a unique membrane-bound BCR, an Ab 
molecule specific for a given Ag. When a B cell recognizes its cognate Ag 
through the BCR, the B cell proliferates and differentiates into a terminally 
differentiated B cell, called plasma cell, able to secrete Abs (also called 
Immunoglobulins, Igs) of the same Ag specificity of its BCR [19]. Secreted 
Igs have two separate functions: one is to bind specifically molecules from 
the pathogens, leading to their neutralization; the other is to mediate the 
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phagocytosis of the pathogen bound to Igs through a process known as 
opsonophagocytosis.  
There are different types of Abs, known as IgM, IgA, IgG, IgD and 
IgE. Each Ig isotype differs in its biological properties and in the capability to 
bind different Ags. All B cells initially express and synthesize IgM, but switch 
to other isotypes upon gene rearrangement, a mechanism known as 
isotype-switch. Abs of switched isotypes maintain their specific Ag-
recognition capacity but differ in other domains of the molecule that 
determine their functionality. IgA are usually present in different mucosal 
body fluids and are important in the control of the local infections. IgG are 
the most abundant Ig isotype present in the serum, and can be divided in 4 
different classes in humans (IgG1, IgG2, IgG3, and IgG4) and in mouse 
(IgG1, IgG2a, IgG2b, and IgG3). IgD are present on the surface of mature 
but not immature B lymphocytes; they bind the Ag and stimulate the cells to 
grow and differentiate in plasma cells. IgE are important against parasite 
infections, and in the allergic reactions. 
Intracellular microbes, such as viruses and some bacteria, can 
survive and proliferate inside phagocytes and other cells, where they are 
inaccessible to circulating Abs. Defense against such infections is a function 
of cell-mediated immunity, which promotes the destruction of microbes 
residing in phagocytes or the killing of i nfected cells to eliminate reservoirs 
of infection.  
T lymphocytes are the cells responsible for the cell-mediated 
immune response; to participate in an adaptive immune response, a naïve T 
cell must first encounter an Ag presenting cell (APC) that presents specific 
antigenic peptide to the TCR. After priming by APCs, naïve T cells can 
proliferate and differentiate into effector or memory T cells [20]. T cells 
belong to two main classes characterized by the cell-surface proteins CD4 
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and CD8. The expression of CD4 and CD8 determines the interactions the 
T cell makes with other cells.  
T cells detect peptides derived from foreign Ags: after Ags are 
degraded within APCs, their peptide fragments are complexed with MHC 
molecules and this complex is displayed on the cell surface. The MHC 
molecules are glycoproteins encoded in the large cluster of genes known as 
the Major Histocompatibility Complex. There are two class of MHC 
molecules, called MHC class I and MHC class II, which differ in both their 
structure and expression pattern on the tissues of the body.  
MHC class I molecules are expressed on virtually all nucleated cells and 
consist of two polypeptide chains. The α chain is encoded in the MHC (on 
chromosome 6 in humans) and is non-covalently associated with a smaller 
chain, β2-microglobulin, which is not polymorphic and is encoded on a 
different chromosome (chromosome 15 in humans). The α chain folds into 
three domains: α1, α2, and α3. The α3 domain and β2-microglobulin closely 
resemble Ig-like domains in their folded structure. The folded α1 and α2 
domains create a long cleft or groove, which is the site at which antigenic 
peptides bind to the MHC molecules. The MHC molecules are highly 
polymorphic, and the major differences between the different forms are 
located in the peptide-binding cleft, influencing which peptides will bind and , 
thus, the specificity of the dual Ag presented to T cells.  
The MHC class II molecules are present only on professional APCs, such 
as DC, B lymphocytes, and M. They consist of a non-covalent complex of 
two transmembrane glycoprotein chains, α and β. The MHC class II α and β 
chains are both encoded within the MHC. Each chain has two domains and 
the two chains together form a compact four-domain structure similar to that 
of the MHC class I molecule. The crystallographic structure of the MHC 
class II molecule shows that it is folded very much like the MHC class I 
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molecule, but in MHC class II molecules the peptide-binding cleft is formed 
by two domains from different chains, the α1 and β1 domains. The major 
differences lie at the ends of the peptide-binding cleft, which are more open 
in MHC class II molecules than in MHC class I molecules. Consequently, 
the ends of a peptide bound to MHC class I molecules are substantially 
buried within the molecule, whereas the ends of peptides bound to MHC 
class II molecules are not.  
Each MHC molecule binds a wide variety of different peptides, but the 
different variants preferentially recognize sets of peptides with particula r 
sequence and physical features. Peptides derived from intracellular 
pathogens that multiply in the cytoplasm are carried to the cell surface by 
MHC class I molecules and presented to CD8 T cells. These cells 
differentiate into cytotoxic T cells that kill the infected cells. Antigenic 
peptides derived from pathogens multiplying in intracellular vesicles and 
those derived from phagocytosed extracellular bacteria and toxins are 
carried to the cell surface by MHC class II molecules and presented to CD4+ 
T cells [20].  
 
1.5 CD4
+
 T cells 
Upon encountering microbial pathogens, Ag-inexperienced, “naïve” 
CD4+ T cells can differentiate into 4 (and possibly more) effector T helper 
(Th) cell subsets with different cytokine profiles and distinct effector 
functions. In this manner, they tailor their responses to the character of the 
threat encountered, providing help to B lymphocytes and CD8+ T cells, and 
activating the cells of the innate immune system. 
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The differentiation of naïve CD4+ T cells into effector Th cells is 
initiated by engagement of their TCR (signal 1) and costimulatory molecules 
(signal 2) by the specific antigenic peptide complexed to MHC class II 
molecules, in the presence of a complex network of specific cytokines 
(signal 3) produced by the innate immune system upon encounter of 
pathogens [21].  
Naïve CD4+ T cells differentiate into T helper type 1 (Th1), Th2, 
Th17, or T regulatory (Treg) lineages depending on the instructional cues 
delivered during initial activation (Figure 1.2) [22].  
Interleukin (IL)-12, produced by APCs, initiates the differentiation of Th1 
cells, which express the signature transcription factor T-bet and secrete the 
signature cytokine interferon (IFN)- that in turn drives Th1 differentiation. 
Th1 cells protect the host against infections with intracellular pathogens [23]. 
In contrast, IL-4 triggers the differentiation of Th2 cells that express GATA-3 
as signature transcription factor and secrete IL-4 as signature cytokine. Th2 
cells eradicate extracellular pathogens and help B cells to produce Abs [24] 
[25].  
Th17 cells are a more recently described effector cell lineage that develops 
via cytokine signals distinct from, and antagonized by, products of the Th1 
and Th2 lineages [26]. Th17 cells express RORt as signature transcription 
factor and secrete IL-17A (IL-17) as signature cytokine. Th17 cells 
contribute to clearance of extracellular bacterial and fungal infections [27] 
[28].  
Treg cells express the signature transcription factor Foxp3 [29]. They 
suppress immune reactions and ensure that our intrinsically self-recognizing 
repertoire of lymphocytes does not mount a response against our own 
tissues or innocuous environmental Ags [30]. Studies have shown that 
these cells function by an as yet unclear mechanism of cell-to-cell contact 
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and/or the production of suppressor cytokines such as IL-10 and 
transforming growth factor-β (TGF-β) [31] [32]. 
A number of variables influence CD4+ Th cell differentiation, 
including TCR affinity for peptide/MHC complex, Ag dose, costimulatory 
signals, and the local concentration of inflammatory cytokines [22]. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Helper T-cell differentiation. Cell differentiation from naïve CD4+ cells 
into the various functional subtypes (e.g., Th1, Th2, Th17, and Treg cells) primarily 
depends on the action of cytokines as indicated (modified  from  [33]). 
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1.5.A Th1 cells 
Th1 cells mediate the elimination of intracellular pathogens through 
IFN-. IFN-can promote M to express inducible nitric oxide synthase 
(iNOS) and other factors to eliminate intracellular pathogens. Another 
function of IFN- is to deliver the isotype switch signal for B cells to produce 
IgG2a Abs [24].  
There are several transcription factors that are required for Th1 cell 
differentiation: signal transducers and activators of transcription (STAT)1, 
STAT4, and T-bet are the best characterized. IL-12 is a cytokine produced 
by DC that activates STAT4, which positively regulates many aspects of the 
Th1 genetic program. STAT1 is activated in response to IFN- signaling and 
reinforces the Th1 phenotype in a positive feedback loop. STAT1 and 
STAT4 also contribute to the regulation of Tbx21, the gene that encodes    
T-bet. T-bet is a T-box transcription factor that is required for the induction 
of many Th1 signature genes. T-bet is also needed for the repression of 
genes specific to alternative T helper cell developmental programs [34]. 
 
1.5.B Th2 cells 
Th2 cells produce IL-4, IL-5, IL-13, and IL-6 and mediate the 
clearance of large extracellular pathogens such as helminthes. Th2 cells are 
also involved in the isotype switching of B cells to produce IgE and thus in 
allergic reactions [24].  
IL-4 is the critical cytokine that drives Th2 development [35]. Upon 
binding to its receptor, IL-4R, IL-4 can initiate the phosphorylation and 
activation of Janus activated kinase (JAK)1 and JAK3, which in turn 
phosphorylate IL-4R subunits [36]. Phosphorylated IL-4 receptors can 
18                                                                                                                            CHAPTER 1 
 
further recruit and activate STAT6 through phosphorylation. Phosphorylated 
STAT6 forms a dimer, which can enter the nucleus and initiate the 
transcription of Th2-specific genes. GATA3 activates expression of the Th2 
cytokine locus, binding to multiple sites proximal and distal to IL-4, IL-5, and 
IL-13 genes [37]. GATA-3 is assumed to be the central factor whose 
level/activity decides the fate of Th cell differentiation, not only through its 
capacity to induce Th2 cytokine production, but also through its capacity to 
block Th1 cytokine production via down-regulation of STAT4 [38]. 
 
1.5.C Th17 cells 
Th17 cells are a more recently described lineage of CD4+ effector  
T cells characterized by production of IL-17 [39] [40] [26].  
Th17 differentiation has been linked to TGF- and IL-6 in mice. IL-6 
suppresses TGF-–induced Foxp3 expression and Treg generation, 
promoting the development of Th17 cells, suggesting that Treg cells and 
Th17 effectors differentiate from the same precursor in a mutually exclusive 
fashion, depending on whether they are activated in the presence of TGF- 
or TGF- plus IL-6 [41]. Moreover, TGF- acts in Th17 development to 
confer IL-23 responsiveness [42]. IL-23 is dispensable for the differentiation 
of Th17 cells, but it is indispensable for a fully effective, protective Th17 
response [43]. In addition, IL-6 and TGF greatly promote chromatin 
remodeling of the Il17-Il17f locus [44], which is further reinforced by IL-23 
[45] [46]. At the transcriptional level, the differentiation of Th17 lineage 
induced by cytokines requires the retinoic orphan nuclear receptors t or , 
RORt or ROR, which are selectively expressed in Th17 cells. RORt and 
ROR are lineage-specifying master regulators in Th17 development and 
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induce the transcription of the genes encoding IL-17A and the related 
cytokine IL-17F. RORt and ROR are induced by TGF- and IL-6 in a 
STAT3-dependent manner [27] [47]. Indeed, overexpression of a 
hyperactive STAT3 enhancs Th17 differentiation, whereas STAT3 
deficiency impairs Th17 differentiation in vitro [45] and in vivo [46].  
Th17 differentiation is negatively regulated by IFN-, IL-4, IL-27, and IL-2 [48] 
[49] [50]. STAT3 upregulates the transcription factor Aiolos in T lymphocytes 
and silences the gene encoding IL-2 thus limiting Th17 expansion [51].  
Recently, IL-21 was reported as an autocrine factor induced by IL-6 to 
regulate Th17 differentiation in combination with TGF- [52] [46] although 
not as efficiently as IL-6+TGF-. TGF- and IL-6 together initiate the 
differentiation of Th17 cells, which in turn can produce IL-21 and thus further 
amplify the Th17 differentiation process [53]. STAT3 is necessary for IL-6 
induction of IL-21 expression and is required for IL-21–mediated Th17 
differentiation [52].  
Th17 cells produce IL-17A, IL-17F, which share 55% sequence identity [54], 
and IL-22, all of which induce a massive tissue reaction [55] [56] [57] [58].  
Th17 cells have considerable plasticity and readily acquire the 
ability to produce IFN- in addition to IL-17 production or completely shut off 
IL-17 production in vitro [59] [14] [60] [61] [62]. Hirota et al. suggested that 
the fate of Th17 cells is shaped by different inflammatory conditions in vivo, 
which allow distinct patterns of plasticity. Whereas IFN- producing “ex-Th17” 
cells that are linked to pathogenicity develop under chronic inflammatory 
conditions, clearance of an infection that results in resolution creates an 
anti-inflammatory environment that precludes Th17 cell plasticity and the 
adoption of the production of alternative cytokines (bona fide Th17 cells) 
[63]. 
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1.6 IFN family and IFN receptor 
The IFNs were originally discovered as agents that interfere with 
viral replication [64]. Initially, they were classified by the secreting cell type 
but are now classified into type I and type II according to receptor specificity 
and sequence homology.  
The type I IFNs are comprised of multiple IFN-α subtypes (14-20, 
depending on species), IFN-β, IFN-ω, and IFN-τ, all of which are structurally 
related and bind to a common heterodimeric receptor. Although type I IFNs 
are secreted at low levels by almost all cell types, hematopoietic cells are 
the major producers of IFN-α and IFN-ω, whereas fibroblasts are a major 
cellular source of IFN-β [65]. IFN-β is also produced by M under 
appropriate stimulus. Viral infection is the classic stimulus for IFN-α and 
IFN-β expression [65] [66]. Secretion of IFN-τ has only been reported in 
ruminants [67].  
IFN- is the sole type II IFN. It is structurally unrelated to type I IFNs, 
binds to a different receptor, and is encoded by a separate chromosomal 
locus. Initially, it was believed that CD4+ Th1 lymphocytes, CD8+ cytotoxic 
lymphocytes, and NK cells exclusively produced IFN- [65] [68]. However, 
there is now evidence that other cells, such as B cells, natural killer T (NKT) 
cells, and APCs secrete IFN-  [69]. IFN- production by professional APCs 
acting locally may be important in cell self-activation and activation of 
nearby cells [70] [71]. IFN- secretion by NK cells and possibly professional 
APCs is likely to be important in early host defense against infection, 
whereas T lymphocytes become the major source of IFN- in the adaptive 
immune response [70] [72].  
IFN- production is controlled by cytokines secreted by APCs, most 
notably IL-12 and IL-18. These cytokines serve as a bridge to link infection 
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with IFN- production in the innate immune response. M recognition of 
many pathogens induces secretion of IL-12 and chemokines [e.g., 
macrophage-inflammatory protein-1α (MIP-1α)]. These chemokines attract 
NK cells to the site of inflammation, and IL-12 promotes IFN-  synthesis in 
these cells. In M, NK and T cells, the combination of IL-12 and IL-18 
stimulation further increases IFN- production.  
Negative regulators of IFN-  production include IL-4, IL-10, TGF-β, and 
glucocorticoids [73].  
Given the complexity of IFN- regulation, it is not surprising that 
inbred mouse strains vary in their ability to secrete this cytokine; for 
example, T lymphocytes of C57BL/6 mice secrete significantly higher 
amounts of IFN- compared with the T lymphocytes of BALB/c mice. 
Increased IFN- production in these strains is associated with greater 
resistance to bacteria and viruses [74] [75] [76].  
Both the type I IFN receptor and the type II IFN receptor have 
multichain structures, which are composed of at least two distinct subunits: 
IFNAR1 and IFNAR2 for the type I IFN receptor, and IFNGR1 and IFNGR2 
for the type II IFN receptor. Each of these receptor subunits interacts with a 
member of the JAK family [77] [78]. In the case of the type I IFN receptor, 
the IFNAR1 subunit is constitutively associated with tyrosine kinase 2 
(TYK2), whereas IFNAR2 is associated with JAK1 [79] [77] [48] [80]. In the 
case of the type II IFN receptor, the IFNGR1 subunit associates with JAK1, 
whereas IFNGR2 is constitutively associated with JAK2 [79] [10]. The initial 
step in both type-I and type-II-IFN-mediated signaling is the activation of 
these receptor-associated JAKs, which occurs in response to a ligand-
dependent rearrangement and dimerization of the receptor subunits, 
followed by autophosphorylation and activation of the associated JAKs. 
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Activation of IFN-receptor–associated JAKs seems to regulate, either 
directly or indirectly, several other downstream cascades. Such diversity of 
signaling is consistent with the pleiotropic biological effects of IFNs on target 
cells and tissues. 
IFNs are defined by their ability to block virus replication. In addition 
to this property, these potent cytokines have many other effects on cellular 
physiology, especially in cells of the immune system.  
Types I and II IFN up-regulate multiple functions within the class I Ag 
presentation pathway to increase the quantity and diversity of peptides 
presented on the cell surface in the context of class I MHC. Up-regulation of 
cell-surface class I MHC by IFN- is important for host response to 
intracellular pathogens, as it increases the potential for cytotoxic T-cell 
recognition of foreign peptides and thus promotes the induction of cell -
mediated immunity.  
IFN-  alone can efficiently up-regulate the class II Ag presenting pathway 
and thus promote peptide-specific activation of CD4+ T cells.  
IFN- is a major product of Th1 cells and further skews the immune 
response toward a Th1 phenotype.  
One of the most important effects of IFN- on M is the activation of 
microbicidal effector functions. M activated by IFN- display increased 
pinocytosis and receptor-mediated phagocytosis as well as enhanced 
microbial killing ability. IFN-–activated microbicidal ability includes induction 
of the NADPH-dependent phagocyte oxidase (NADPH oxidase) system 
(“respiratory burst”), priming for NO production, tryptophan depletion, and 
up-regulation of lysosomal enzymes promoting microbe destruction. Similar 
microbicidal mechanisms are activated by IFN- in N [69]. 
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Most, if not all, of these effects are mediated by the products of 
cellular genes, whose expression is highly induced by IFN treatment of cells. 
These IFN-stimulated genes (ISGs) number in the hundreds, but the 
biochemical and cellular functions of only a handful of them have been 
delineated as yet [81]. Some of these genes are regulated by both type I 
and type II IFNs, whereas others are selectively regulated by distinct IFNs 
[82].  
 
1.7 IL-17 cytokine family and IL-17 receptors 
The best characterized member of IL-17 family is IL-17A (IL-17). 
The five additional IL-17 family members are IL-17B to IL-17F. Among the 
IL-17 family members, the IL-17F isoforms 1 and 2 have the highest degree 
of homology with IL-17A (55 and 40% respectively), followed by IL-17B 
(29%), IL-17D (25%), IL-17C (23%), and IL-17E (also named IL-25) being 
most distant (17%). Th17 cells produce only IL-17A and IL-17F [83]. 
Although produced by T cells, IL-17 acts primarily on epithelial, 
endothelial and stromal cells. Genes induced by IL-17 encode antimicrobial 
proteins (-defensins, cathelicidins, RegIII, lipocalin 2, salivary histatins), 
N-activating factors (granulocyte colony-stimulating factor, G-CSF, and 
CXC chemokines), and inducers of the acute phase response (IL-6) [84]. 
IL-17A and IL-17F have distinct biological effects. Studies 
comparing    Il17a–/– mice with Il17f–/– mice indicate that IL-17A has a more 
important role in driving auto-immunity than IL-17F, probably owing to its 
more potent signaling strength [85]. Instead, both IL-17A and IL-17F are 
important for host defense against opportunistic infections [86]. IL-17F-
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induced responses are 10-30 fold weaker in terms of downstream gene 
activation than those of IL-17A, with IL-17A–IL-17F heterodimers having an 
intermediate activity [87]. 
A striking feature of IL-17A, IL-17F, and IL-17A/F is their modest 
signaling activity, even at high concentrations. However, they exhibit potent 
synergy, not only with tumor necrosis factor (TNF) but also with lymphotoxin 
(LT), IFN-, and IL-1. The mechanisms underlying synergy are not fully 
defined, but a major component is cooperative enhancement of mRNA 
stability of certain IL-17 target genes [84] [88]. 
The receptor for IL-17A, IL-17F and the IL-17A/F heterodimer is 
composed of IL-17RA paired with IL-17RC [84]. There are notable 
differences between the human and mouse IL-17R systems. Human         
IL-17RA has much higher affinity for IL-17A than for IL-17F, and human IL-
17RC binds both ligands with similar affinity. By contrast, murine IL -17RC 
alone binds primarily to IL-17F [89] [54]. 
After either IL-17RA or IL-17RC bind their respective ligand, affinity 
for the reciprocal subunit is increased [89]. IL-17 receptor signaling requires 
the adaptor Act1 and results in the activation of the transcription factor 
nuclear factor (NF)-κB and mitogen-activated protein (MAP) kinases [88].  
IL-17RC expression is limited to non-hematopoietic cells whereas 
IL-17RA is expressed ubiquitously, at particularly high levels in lymphoid 
tissues such as thymus, spleen, and lymph nodes [86]. This expression 
pattern is interesting, as the main responses to IL-17A occur in epithelial 
cells, endothelial cells, and fibroblasts, although M and DC are also 
responsive (reviewed in [90]). Only a limited number of IL-17A–induced 
genes has been documented in lymphocytes, and these genes are distinct 
from those induced by IL-17A in other cell types [86]. Although its 
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expression is widespread, IL-17RA can be dynamically regulated; for 
example,  phosphoinositide 3-kinase (PI3K) limits the expression of IL-17RA 
by T cells [84]. This could be biologically important, as IL-17A–induced 
signaling strength correlates with cell surface expression levels of IL-17RA; 
in contrast to most cytokine receptors, high levels of IL-17RA seem to be 
required for effective responses to IL-17A [91] [92]. Another function of      
IL-17RA might be to limit signaling by receptor-mediated internalization of 
the ligand. Indeed, surface expression of IL-17RA rapidly decreases after 
IL-17A binding, theoretically internalizing IL-17A and clearing it from the 
inflammatory milieu [93]. 
A number of genetic disorders have begun to reveal that IL-17 is 
surprisingly determinant to control just a few infections, namely those 
caused by Candida albicans and Staphylococcus aureus. Humans with 
hyper-IgE syndrome (HIES or Job’s Syndrome) have mutations in STAT-3. 
Presumably because of defects in signal transduction of Th17-inducing 
cytokines such as IL-6, IL-21 and IL-23, which activate STAT-3, these 
patients exhibit a selective paucity of Th17 cells  [94] [95] [96]. HIES patients 
exhibit a wide spectrum of clinical manifestations and are highly susceptible 
to mucosal candidiasis and staphylococcal abscesses, implicating Th17 
cells in immunity to these organisms. Moreover, Il17a–/– Il17f–/– mice develop 
spontaneous S. aureus skin abscesses [86]. 
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1.8 Immune response to natural S. aureus infection 
Polymorphnuclear (PMNs) cell recruitment is the primary host 
response to S. aureus infection [15]. Indeed, patients with N disorders, 
such as chronic granulomatous disease and Job’s syndrome, suffer from an 
increased incidence of S. aureus infections [97] [98].  
Both Abs and complement enhance the bactericidal effect of N and 
indeed the presence of opsonizing Abs directed against S. aureus capsule 
or PGN facilitates phagocytosis in vitro [3] [99]. Nevertheless, the role of 
Abs in clearing the staphylococcal infection in vivo is less certain since the 
titer of anti-staphylococcal Abs is not correlated with protection from 
infection. Moreover patients with defects in humoral immunity are not 
particularly prone to S. aureus infection. For example, patients with 
hereditary (X-linked) agammaglobulinemia rarely have clinically important   
S. aureus infections, although Streptococcus pneumoniae and 
Pseudomonas species are a serious problem for these patients [100] [101], 
often leading to death. In these subjects, the lack of Abs against S. aureus 
must be compensated for by other immune mechanisms.  
Recent studies showed the importance of Th17 cells and IL-17 for 
protection against S. aureus infections [102] [103]. IL-17, produced by Th17 
cells, is crucial for N recruitment and activation [103]. Of interest, Il17a–/– 
Il17f–/– mice develop spontaneous S. aureus skin abscesses [86] and 
humans with IL-17 defects are also prone to S. aureus skin infections [104]. 
Further support for the involvement of Th17 cells in S. aureus immunity 
comes from studies of bacterial pneumonia in mice [105]. It has been shown 
that influenza A inhibits Th17-mediated host defense in mice via induction of 
type I IFNs. This caused impaired bacterial clearance of S. aureus and 
resulted in increased mortality. Treating mice with exogenous IL-23 
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stimulated production of IL-17 and IL-22, which markedly improved 
clearance of S. aureus and reduced mortality. Of note is that the highly 
virulent community-associated methicillin-resistant S. aureus strains can 
induce type I IFNs within the lungs of mice [106], thereby inhibiting the Th17 
cell pathway. All these evidences tie together cell-mediated immunity and 
N effector activities, with Abs playing a supportive role for opsonization 
and/or neutralization of virulence factors.  
The innate immune system contributes to protection from S. aureus 
infection through activation of Toll-like receptor (TLR)2/6 and myeloid 
differentiation primary response protein (MyD)88 pathways by 
staphylococcal surface components [6] [107]. Moreover, S. aureus             
α-hemolysin activates the immune system via a TLR2-independent 
mechanism whereby NOD2 signaling results in protection against S. aureus 
murine skin infections [108] [109].  
However, the immune system is thwarted  by multiple staphylococcal 
virulence factors: toxins that lyse phagocytes, capsule that prevents efficient 
opsonization, protein A that inhibits the opsonic activity of Abs and induces 
apoptosis in B cells, adhesins to host tissues that allow uptake by non-
professional phagocytes thereby providing a site hidden from the immune 
system, and anti-immune system factors that target Abs, complement, 
selectins, intercellular adhesion molecule 1 (ICAM-1), and innate immune 
system receptors [110] [111] [112]. These entire virulence factors enable    
S. aureus to evade the host immune response. 
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1.9 Vaccines  
Vaccines are among the greatest successes in the history of public 
health. Vaccines have now led to the eradication of smallpox, near 
eradication of polio, and prevention of untold millions of deaths from 
infectious diseases each year, and are one of the most effective public 
health measures available [113].  
Vaccines are biological products that mimic a disease-causing agent thus 
stimulating the immune system to mount a response against it. An ideal 
vaccine will induce the expansion and maturation of naïve pathogen-specific 
lymphocyte clones that exist at low frequency in uninfected or unimmunized 
individuals [114].  
Immunization can be derived from either passive or active means. 
Passive immunization occurs with the transfer of preformed Abs to an 
unimmunized individual, who would then develop a temporary immunity to a 
particular organism or toxin due to  the presence of these Abs. Once Abs 
have been eliminated, the individual would no longer have immunity to the 
microorganism or toxin. Active immunization occurs with the exposure of an 
unimmunized individual to an Ag against which the immune system would 
then develop immunity. In contrast to passive immunization, active 
immunization typically produces long-term immunity due to the stimulation 
of the immune system.  
Long-term protection requires the persistence of vaccine-specific 
Abs and/or the generation of immune memory cells capable of rapid and 
effective reactivation upon subsequent microbial exposure. The 
determinants of immune memory induction, as well as the relative 
contribution of persisting Abs and of immune memory to protection against 
specific diseases, are thus essential parameters of long -term vaccine 
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efficacy. The predominant role of B cells in the efficacy of current vaccines 
should not shadow the importance of T-cell responses: T cells are essential 
to the induction of high-affinity Abs and immune memory, and novel vaccine 
targets have been identified against which T cells are likely to be the prime 
effectors [115]. 
 
1.10 Vaccines against S. aureus 
S. aureus has demonstrated its versatility by remaining a major 
cause of morbidity and mortality despite the introduction of several new 
antibiotics to treat methicillin-resistant S. aureus infections. Therefore, 
effective vaccination against S. aureus would be a major health 
achievement. 
Despite the continued efforts by a combination of university, small biotech, 
and large pharmaceutical company researchers  to develop a S. aureus 
vaccine, multiple clinical trials have failed.  
The first vaccine against S. aureus tested in humans was StaphVax. 
It included S. aureus capsular polysaccharides type 5 and 8 (CP5 and 8) 
conjugated with recombinant Pseudomonas aeruginosa exoprotein A. The 
vaccine failed in phase III clinical trial. It has recently been shown that         
S. aureus USA300, one of the most important c lones worldwide, has no 
detectable capsule due to a point mutation in the promoter region of cap-5, 
necessary for CP5 biosynthesis [116]. Moreover, the role of CPs in             
S. aureus virulence is not clear and their expression is limited to the 
stationary phase [7] [117]. These reasons may have contributed to vaccine 
failure. 
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Another vaccine against S. aureus was V710, based on a single 
surface staphylococcal protein, IsdB [99] [118]. IsdB is a protein conserved 
and expressed throughout different S. aureus strains, which mediates iron 
uptake from hemoglobin [99] [119]. Immunization with IsdB formulated on 
amorphous aluminum hydroxyphosphate sulfate adjuvant increased murine 
Ab titers by up to 20-fold. Increased Ab titers correlated with enhanced 
survival in a murine disseminated challenge model. Also, monoclonal Ab to 
IsdB had in vitro opsonophagocytic activity and efficacy in rodent challenge 
models [99]. The phase II/III vaccine clinical trial was interrupted; the reason 
is not yet completely understood [118].  
A number of passive approaches have also been undertaken: 
Veronate, based on polyclonal Ab against the S. aureus surface protein ClfA; 
Altastaph, containing CP5 and CP8 Abs purified from subjects vaccinated 
with StaphVax; Tefibazumab, monoclonal Ab against ClfA; and Aurograb, 
single chain Ab against an ATP binding cassette transporter of the pathogen. 
They all failed to show efficacy against S. aureus infection in humans [117] 
[120] [121]. 
Other vaccines are still being evaluated. An investigational vaccine, 
NDV-3, contains the N-terminal portion of the Candida albicans agglutinin-
like sequence 3 protein (Als3p) formulated with an aluminum hydroxide 
adjuvant in phosphate-buffered saline. Preclinical studies demonstrated that 
the Als3p vaccine Ag protects mice from both intravenous challenge and 
skin and soft tissue infection with S. aureus. The vaccine was safe and well-
tolerated in a phase I clinical trial [122]. Protection was found to be 
mediated by T cells, specifically Th17 and Th1 cells, and was lost in mice 
that lacked N producing reactive oxygen species [123]. 
In other studies, mice were immunized with clumping factor A (ClfA). 
ClfA is a fibrinogen-binding surface protein involved in staphylococcal 
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adhesion to host tissues. It was included in a tetra-Ag vaccine that 
underwent a first-in-human (phase I/II) study in the United States [124]. Wild 
type mice were protected from S. aureus infection after immunization with 
ClfA, whereas IL-17A–deficient mice were not [125].  
All the vaccines against S. aureus tested so far in humans failed to 
show protection. As suggested by Bagnoli et al., they all targeted a single 
component of the pathogen. Since S. aureus expresses a plethora of toxins 
and immune evasion factors, efficacy of monovalent vaccines is likely to be 
insufficient in humans. Moreover, animal studies as well as clinical 
observations indicated that both humoral as well as cell-mediated immunity 
are involved. On the basis of that, the authors proposed a model in which 
vaccine efficacy is gained through three major immune responses: (i) Abs to 
directly inhibit bacterial viability and/or toxicity; (ii) Abs to mediate 
opsonophagocytosis; and (iii) cell-mediated immunity to stimulate 
recruitment of phagocytes at the site of infection. It is very likely that only a 
combination of staphylococcal Ags with different properties and functions 
formulated with adjuvants able to elicit a potent Ab production, but also the 
proper cellular response, will satisfy the three criteria [126]. 
 
1.11 Novartis Vaccines vaccine against S. aureus 
Novartis Vaccines has engaged in the research and development of 
an effective vaccine against S. aureus infections. Using different 
approaches, comprising reverse vaccinology, proteomic and comparative 
genomics analyses, a combination of four highly conserved Ags (Combo) 
was selected and proposed as potential vaccine. The vaccine comprises 
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two surface proteins (FhuD2 and Sur2) and two secreted proteins (HlaH35L 
and EsxAB).  
HlaH35L is the non-toxic mutant of Hla, a secreted toxin that 
assembles into a membrane-perforating homoheptamer upon binding to its 
eukaryotic cellular receptor, the membrane-associated protease ADAM10, 
which facilitates Hla-mediated disruption of epithelial integrity [8] [125] [126]. 
Hla expression is down-regulated when bacteria reach a high concentration 
through the agr locus that encodes a quorum-sensing system [127]. The 
substitution of histidine 35 with leucine produced a mutant toxin (H35L) 
without hemolytic or lethal activity, as pore formation on the eukaryotic cell 
membrane is impaired [71]. 
EsxAB derives from the fusion of the proteins EsxA and EsxB.        
S. aureus secretes EsxA and EsxB across the bacterial envelope. 
Staphylococcal esxA and esxB are clustered with six other genes and some 
of these are required for synthesis or secretion of EsxA and EsxB. Mutants 
that fail to secrete EsxA and EsxB display defects in the pathogenesis of    
S. aureus murine abscesses, suggesting that this specialized secretion 
system may be a general strategy of human bacterial pathogenesis [128].   
FhuD2 (ferric hydroxamate uptake) was first discovered as a ferric 
hydroxamate siderophore binding protein, which mediates iron uptake 
through a dedicated ATP binding cassette transporter [129]. The protein 
was demonstrated to have a discrete, punctate localization on the bacterial 
surface, to be important in invasive infection, and function as an efficacious 
vaccine target [130]. 
Sur2 is a highly conserved protein, present in multiple copies 
(paralogs) in all the S. aureus strains sequenced by Novartis Vaccines. The 
protein function is still unknown.  
INTRODUCTION                                                                                                                   33 
 
All 4 vaccine Ags are consistently expressed by clinically relevant 
strains.  
NVD Combo vaccine adjuvanted with alum has shown efficacy in 
pre-clinical mouse models (pneumonia, abscess, and peritonitis model) and 
has recently been tested in a human phase I clinical trial.  
To improve this vaccine further, Combo Ags were formulated with 
alum/SMIP-7.10 (alum-S-7), a novel adjuvant formulation composed of a 
TLR7 agonist (TLR7a) small molecule (SMIP-7.10) adsorbed to alum 
(Figure 1.3). 
 
Figure 1.3 alum/S-7 structure. The TLR7a small molecule is a soluble 
benzonaphtyridine (right) to which a phosphonate group was added via a linker 
(left) to allow adsorption to alum (in blue).  
 
 
Adjuvants that incorporate TLR7a are able to induce more polarized 
Th1 cell responses [117] that have been shown to be important for 
protection against S. aureus [97]. 
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1.12 Vaccine adjuvants 
Vaccines typically contain two main components: one or more Ags 
to which the immune response is desired and an adjuvant that enhances the 
immunogenicity of Ags and that acts accelerating, extending, or improving 
the quality of specific immune responses to vaccine Ags.  
Vaccine adjuvants are represented by different classes of compounds that 
display adjuvant activity in pre-clinical models. These include microbial 
products, mineral salts, emulsions, microparticles, nucleic acids, small 
molecules, saponin, and liposomes, which exert their function by diverse 
and often poorly characterized mechanisms of action [131] [132] [133]. 
Currently, there are very few vaccine adjuvants that are approved 
for human use. Among them there are alum (aluminum hydroxide) and the 
oil-in-water emulsions MF59 and AS03. Alum has been widely used in 
human vaccines for more than 70 years, while MF59 has been licensed for 
human use a decade ago, and AS03 only few years ago. The molecular 
mechanism of action and the target cells of alum, MF59, and AS03 have 
only been under investigation.  
Alum adjuvant consists of precipitates of aluminum hydroxide to 
which Ags are adsorbed. Alum absorption increases Ag uptake [134] and 
stability at the site of injection. In addition, alum induces a local pro -
inflammatory reaction that can increase immunogenicity [6] [108]. Alum is 
used primarily to enhance Ab production and does not uti lize TLRs for its 
function in vivo [109]. In humans, responses to proteins with alum tend to be 
a mix of Th2 and Th1 cells [110]; however, in mice (especially BALB/c mice) 
alum induces a profoundly polarized Th2 cell response, with Th2 cell -
dependent Ab isotypes, to nearly all protein Ags. 
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1.13 Toll-like receptors and their agonists 
TLRs are an evolutionary conserved family of membrane-bound 
PRRs [135] [136] that were named after Drosophila Toll. Toll was firs t 
identified as the product of a gene that was shown to play a critical role on 
the dorso-ventral axis formation of drosophila embryos [137]. The high 
homology between the intracellular regions of Drosophila Toll and 
mammalian IL-1R, as well as the similarity in the signaling pathways 
triggered by these two receptors, both of which result in NF-κB activation, 
led to the hypothesis that Toll could also have a function in the immune 
response [62] [138]. Indeed, Toll is required for Drosophila response to fungi 
being part of a PGN sensing cascade that ends in the production of 
antifungal peptides by cells of the fat body [139] [140]. 
All mammals TLRs play a primary role in innate immune response, 
but are not involved in mammalian development. Humans have ten TLRs, 
each of which plays a distinct role in innate immunity, since each of them 
recognizes a specific microbial pattern [135] [136]. They recognize a broad 
spectrum of pathogen components, such as bacterial and fungal cell wall 
components, bacterial lipoproteins, and bacterial and viral nucleic acids. 
Usually more than one TLR is expressed by the same APC, which during 
infection can be simultaneously stimulated by many of TLRs. Some TLRs 
are expressed at the cell surface, whereas others are expressed on the 
membrane of endocytic vesicles or other intracellular compartments. TLRs 
are composed of a transmembrane ectodomain of leucine-rich repeats 
(LRRs), which are involved directly or through accessory molecules in 
ligand binding, and a cytoplasmatic Toll/interleukin-1 receptor (TIR) domain 
that interacts with TIR-domain-containing adaptor molecules.  
36                                                                                                                            CHAPTER 1 
 
TLR2 can heterodimerize with TLR1 or TLR6 to recognize 
respectively triacyl or diacyl lipopetides, which are present on the surface of 
bacteria. TLR4 is specialized in responding to lipopolysaccharide (LPS) 
expressed by Gram-negative bacteria, while flagellin, a protein of bacterial 
flagella, is recognized by TLR5. All these TLRs are expressed on the cell 
surface and allow the immediate detection and response to microorganisms. 
A second class of TLRs is expressed in the endolysosomal compartment 
and preferentially recognizes microbial nucleic acids that are able to get 
through the cytoplasmic membrane barrier. TLR3 binds double-stranded 
RNA synthesized by viruses. The natural ligand of TLR7 and TLR8 is single 
stranded viral RNA, yet several TLR7a and/or TLR8a small molecule 
immune potentiators (SMIPs) have been described. Among them, 
imidazoquinolines, like Resiquimod (R848) that activates TLR7 and TLR8, 
and Imiquimod (R837) that activates TLR7 only, and purine-like molecules, 
like SM360320 (9-benzyl-8-hydroxy-2-(2-methoxyethoxy)adenine) that 
activates TLR7 only. TLR9 recognizes double-stranded DNA, preferentially 
characterized by unmethylated cytosine guanine oligodeoxynucleotide 
(CpG-ODN) motifs, common to both bacterial and viral DNA. The 
intracellular localization of these TLRs is very important to avoid their 
activation by endogenous nucleic acids, which can lead to autoimmunity 
(Figure 1.4). 
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Figure 1.4 Toll-like receptor localization. TLRs, expressed either on the cell 
surface or on the membrane of endocytic vesicles or intracellular compartments, 
recognize a diverse range of microbial and viral ligands (modified from [141]). 
 
 
TLRs are expressed on many immune and non-immune cells. Their 
expression pattern is different in different DC subsets. Myeloid dendritic 
cells (mDC) express all surface TLRs plus TLR3, TLR7, and TLR8, thus 
mounting very strong anti-bacterial responses, while plasmacytoid dendritic 
cells (pDC) express only TLR7 and TLR9, thus being specialized to face 
viral infections. TLR7 and TLR9 reside in the endoplasmatic reticulum 
before stimulation and are rapidly recruited to endosomal compartment 
upon activation. It has been shown that UNC93B1, a poorly characterized 
multi-transmembrane-domain–containing protein, specifically binds and 
delivers TLR7/9 from the endoplasmatic reticulum to endosomal 
compartment for ligand recognition [142].  
Plasma 
membrane
Endosome
Cell membrane  
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Important differences exist between mice and humans with regard 
to tissue expression and function of TLR7 and TLR8. In both species, TLR7 
is expressed in B cells, N, and pDC; however, in mice TLR7 is expressed 
by M and CD8-, but not CD8+, DC subsets [116]. TLR8, in contrast, is 
expressed by Mo lineage cells and mDC in man, whereas it may not be a 
functional receptor in mice [143]. 
Recently, several synthetic agonists of TLR4, TLR7, TLR8, and 
TLR9 have been identified as a major class of molecules that have potential 
utility as vaccine adjuvants. 
One such adjuvant is the TLR4a monophosphoryl lipid A (MPL), a derivative 
of the bacterial component LPS. MPL adsorbed to alum (known as AS04) is 
currently approved for use against human papilloma virus and hepatitis B 
[144]. Recent studies to elucidate the mechanism of action of AS04 
revealed that AS04 binds TLR4 and promotes cytokine production, Ag 
presentation, and migration of APCs to T-cell area of draining lymph nodes, 
allowing for an efficient priming of naïve T cells [144]. 
Another adjuvant is represented by non-methylated CpG oligonucleotide 
used in both preclinical and clinical studies as adjuvant in cancer vaccines 
[145]. CpG acts through TLR9 expressed by human pDC and B cells 
inducing humoral and cellular responses. 
The TLR7/8 pathway, specialized in recognition of single stranded viral RNA 
pathways, has demonstrated promising pre-clinical results as a target for 
potential vaccine adjuvant. Small molecules TLR7a, such as Imiquimod, or 
TLR7/8a, such as Resiquimod, were shown to improve the immunogenicity 
of a variety of vaccine adjuvants if adequately formulated or directly 
conjugated to protein Ags [145] [146]. Imiquimod has demonstrated 
immunomodulating effects as a topic vaccine adjuvant. Injection of 
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immature DC into Imiquimod-pretreated skin led to DC activation and 
migration to draining lymph nodes in cancer patients, as well as to 
enhanced DC immunostimulatory capacity [145]. Importantly, Imiquimod is 
licensed as a topical therapy for malignant and non-malignant skin cell 
disorders, demonstrating a safety and efficacy track record for this class of 
TLRa as therapeutics. 
 
1.14 Rationale and aims 
The aim of the PhD project described in this thesis is to characterize 
the immune responses elicited by the novel Combo vaccine formulation with 
the alum/S-7 adjuvant, and to compare its efficacy to that induced by 
Combo±alum. 
For this purpose, a mouse model of S. aureus-induced peritonitis 
was chosen. Peritonitis remains a frequent complication of continuous 
ambulatory peritoneal dialysis (CAPO), a major form of renal replacement 
therapy worldwide. This is despite the considerable improvements made in 
the delivery systems, which have significantly reduced peritonitis incidence 
[147] [148] [149]. Moreover, intraperitoneal challenge has been utilized in 
studies examining the efficacy of vaccine Ags targeting S. aureus, owing to 
the ability to easily deliver large inocula and generate highly reproducible 
data in lethal dose challenge experiments [150] [151] [152] [153]. 
S. aureus Newman strain, used in this study, was isolated in 1952 
from a human infection [154]. It has been used extensively in animal models 
of staphylococcal disease due to its robust virulence phenotypes.  
BALB/c mice were immunized once intramuscularly (i.m.) with 
Combo+alum or Combo+alum/S-7 and challenged intraperitoneally (i.p.) 
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with a lethal dose of S. aureus Newman strain 12 days after the 
immunization. Combo+alum/S-7 efficacy was compared to that of 
Combo±alum and vaccine-specific humoral and T-cell responses were 
characterized. Experiments with B-cell ko JH mice and serum transfer 
studies, CD4+ effector T-cell depletion and IL-17A/IFN- in vivo 
neutralization experiments were performed to determine the arm of the 
immune response essential for protective immunity against S. aureus 
peritonitis conferred by Combo+alum/S-7 immunization. 
 
 
 
 
 
 
 
 
 
  
 
 
Chapter 2 
Materials and methods 
 
2.1 Cloning and purification of vaccine antigens 
Vaccine Ags were amplified by PCR from S. aureus NCTC8325 
strain and cloned as tagless constructs. Proteins were purified and 
suspended in 10 mM potassium phosphate, pH 7.2 (5 mM EDTA was added 
for EsxAB buffer). Endotoxin content was controlled with limulus 
amoebocyte lysis (LAL) test. 
 
2.2 Vaccine antigen formulation with alum or alum/S-7 
Ags were adsorbed to alum by incubating 10 µg of each Ag with      
2 mg/ml aluminum hydroxide±0.5 mg/ml SMIP-7.10, at pH 6.5-7 and 
osmolality 0.308±0.060 Osm/Kg, with slow stirring for few hours at room 
temperature (RT).  
The formulation pH and osmolality were controlled with the use of a 
pH meter (Eutech Instruments) and an osmometer (Gonotech), respectively.  
42                                                                                                                            CHAPTER 2 
 
To control Ag adsorption to alum or alum/S-7 and protein integrity, 
formulations were analyzed by SDS-PAGE. Samples were centrifuged for 
10 min at 13,000 rpm. Pellets were suspended in 100 µl of 4X desorption 
buffer (40% Glycerol, 240 mM Tris/HCl pH 6.8, 8% SDS, 0.04% 
bromophenol blue, 5% beta-mercaptoethanol, 0.5 M KH2PO4) and 
denatured for 30 min at 100°C. 200 µl of supernatant from each sample 
were treated with 10 µl of 0.5% deoxycholate (DOC) for 10 min and then 
with 8.5 µl of 60% trichloroacetic acid (TCA) and finally centrifuged for 10 
min at 13,000 rpm. Supernatant was then removed and pellet was 
suspended in 10 µl of 4X loading buffer (40% Glycerol, 240 mM Tris/HCl pH 
6.8, 8% SDS, 0.04% bromophenol blue, 5% beta-mercaptoethanol) plus 10 
µl Tris-HCl pH 8.5 and denatured 30 min at 100°C. 10 µl of denatured pellet 
and 20 µl of denatured supernatant were loaded on a 4-12% Bis-Tris gel 
(Invitrogen). 
Finally, to control SMIP-7.10 adsorption to alum, samples were 
analyzed by HPLC. An aliquot of each sample was centrifuged 10 min at 
13,000 rpm and the supernatant was diluted 1:2 in 10 mM NaOH. A second 
aliquot was treated with an equal volume of 1 M KH2PO4  pH 9 for 30 min at 
100°C, shaking, and then centrifuged for 10 min at 13,000 rpm. Finally, the 
supernatant was diluted 1:5 in 10 mM NaOH. The standard curve was 
prepared with 1:2 serial dilutions of SMIP-7.10 in 10 mM NaOH pH 9.  
SMIP-7.10 content in the two aliquots of each sample was determined by 
HPLC-UV (high performance liquid chromatography-ultraviolet) (Waters). 
The analytical column was C18, UV wavelength was 268 nm, and the 
mobile phase was a gradient of 1% trifluoroacetic acid (TFA) in water and 
0.1% TFA in water at flow rate of 1.2 ml/min. 
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2.3 Animal care and compliance statement 
Mice were monitored daily and euthanized at the appearance of 
humane endpoints, in accordance with Novartis Animal Welfare Policies and 
Italian laws. Experimental protocols were reviewed and approved by the 
Italian National Institute of Health, ISS (Istituto Superiore di Sanità). Five-
week old female BALB/c mice, purchased from Charles River Laboratories, 
and five-week old JH mice and matching BALB/c mice, purchased from 
Taconic, were used for the experiments.  
 
2.4 Immunization studies 
For active immunization, BALB/c mice were immunized once i.m. 
with: 
 Combo: 10 µg of each purified Ag (HlaH35L, EsxAB, FhuD2, and Sur2) 
in solution.  
 Combo+alum: 10 µg of each purified Ag adsorbed to aluminum 
hydroxide (alum, 2 mg/ml). 
 Combo+alum/S-7: 10 µg of each purified Ag adsorbed to alum (2 
mg/ml) together with 50 µg SMIP-7.10. 
50 µl of vaccine were injected in each hind leg quadricep (100 µl/mouse). 
Control mice received equal amounts of saline, alum, or alum/S-7. 
For passive immunization studies, pools of sera were prepared from 
BALB/c mice vaccinated either with Combo+alum/S-7 or alum/S-7 alone 32 
days before bleeding. One hundred and fifty microliters of these pooled sera 
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were injected in the tail vein of naive BALB/c mice the day before infection 
with S. aureus. 
 
 
 
 
 
Figure 2.1 Experimental design of active immunization studies. BALB/c mice 
were immunized i.m. on day 0 and challenged i.p. with S. aureus on day 12. Mice 
survival was monitored for 15-30 days. 
 
2.5 Peritonitis model 
Frozen cultures of S. aureus were inoculated 1:25 into fresh tryptic 
soy broth and grown for 2 h and 30 min with shaking (250 rpm) at 37°C until 
the optical density at 600 nm (OD600) of the bacterial culture diluted 1:10 in 
PBS was between 0.20 and 0.22. Staphylococci were sedimented, washed, 
and suspended in sterile PBS (Gibco) to obtain an inoculum of 5 x 109 
colony forming units (CFU)/ml. Mice were challenged injecting 100 µl of 
bacterial inoculum (5 x 108 CFU) i.p.. Actual CFUs in the inoculum were 
determined plating it at serial dilutions on tryptic soy agar and enumerating 
colonies after overnight (o/n) incubation at 37°C. Infected animals were 
monitored for survival over a period of 15 to 30 days. 
 
i.m. immunization 
0 12 42 
i.p. infection Sacrifice 
Survival rate 
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2.6 Abscess and CFU enumeration 
Fifteen or 30 days after infection, mice were killed by CO2 inhalation 
and subjected to necropsy. Abscesses located at the peritoneal membrane 
were enumerated by visual inspection. Kidneys were excised and 
homogenized in PBS (Gibco) using an automated lab homogenizer (Miltenyi 
Biotec). Homogenates were serially diluted in PBS, plated on tryptic soy 
agar, and incubated o/n at 37°C for CFU enumeration 24 h later.  
 
2.7 Histopathology 
Mouse kidneys were cut in two equal halves along the sagittal plane, 
fixed in 4% buffered formaldehyde, and processed for paraffin embedding. 
Four µm-sections were cut from each kidney and stained with hematoxylin 
and eosin (HE). Images of each HE-stained kidney were acquired by Mirax 
Scan 150 slide scanner (Zeiss) equipped with 40x lens. Two sections for 
each kidney were examined. 
 
2.8 Combo-specific antibody quantification 
For serum collection, mice were bled 12 or 32 days after the 
immunization. Blood was kept at RT for 1 h in the untreated collection tubes, 
and then centrifuged 15 min at 1,500 × g, 4°C. Serum was collected and 
stored at -20°C until the day of analysis.  
Ag-specific Abs in serum were quantified using Luminex Tecnology 
(Luminex® Corporation) as described below.  
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2.8.A Multi-analyte COOH microspheres 
Ags were covalently conjugated to the free carboxyl groups on 
xMAP multi-analyte COOH microspheres (Luminex Corporation). 
Carboxylated microspheres were brought to RT and sonicated, followed by 
vortexing for approximately 1 min. An aliquot of 2.25 x 107 microspheres 
from the stock vial was added to a clear 1.5 ml copolymer microcentrifuge 
tube and pelleted by centrifugation. Microspheres were then washed with 
500 μl of 0.1 M NaH2PO4 pH 6.2, suspended by sonication and then 
pelleted. To activate the carboxyl sites on microspheres, 10 μl of a 50 mg/ml 
solution of N-hydroxysulfosuccinimide (sulfo-NHS; Pierce) and 10 μl of a 50 
mg/ml solution of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
hydrochloride (EDC; Pierce) solution were added to microspheres 
suspended in 480 μl of 0.1 M NaH2PO4. Tubes were incubated for 30 min at 
RT in the dark.  Following activation, microspheres were washed with 500 μl 
of either 50 mM 2-(N-morpholino) ethan sulfonic acid buffer pH 5.0 (MES; 
Sigma) to remove residues of EDC and sulfo-NHS. 
 
2.8.B Coupling 
0.02 mg of each Ag were incubated for 2 h at RT in a 1.5 ml 
eppendorf with activated beads. At the end of this time, beads were washed 
with solution PBS 1x + 0.05% Tween-20 and stored in a solution PBS 1x + 
0.02% Tween-20 + 0.1% BSA (BSA blocks activated sites remaining on the 
beads). 
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2.8.C Test coupling 
Pre-mixing of beads is necessary to test the beads coupling and to 
ensure that there is no cross-reactivity between beads coupled to the 
different Ags. 50 µL of internal control sera were loaded in a plate with 5 µL 
of pre-mixed beads per well, incubated for 30 min at RT and then washed. 
50 µL of phycoeritrin (PE) secondary Ab was added and incubated for 15 
min at RT. The plate was washed two times and 200 µL of PBS 1x were 
added for the instrument reading. 
 
2.8.D Assay 
Sera were diluted 1:10,000 in PBS buffer 1x. 50 µL of sera were 
loaded in a 96-well microtiter plate. The plate was incubated 30 min at RT 
and then washed with PBS 1x. 50 µl of a solution of PE-anti-mouse IgG 
1:200 in dilution buffer were dispensed in each well of the plate with 50 µL 
of PBS buffer 1x. The plate was incubated 15 min at RT and then washed. 
200 µl of PBS buffer 1x were dispensed in each well of the plate and then 
Luminex reading started. The reader detected individual beads by flow 
cytometry. The fluidics system of the reader aligned the beads into single 
file as they enter a stream of sheath fluid and then a flow cell. Once the 
beads were in single file within the flow cell, each bead was individually 
interrogated for bead color (which corresponded to a particular S. aureus Ag) 
and assay signal strength (PE fluorescence intensity) after excitation at 532 
nm. The median fluorescence intensity (MFI) emitted by PE at 575 nm was 
directly proportional to the amount of Ab bound to microspheres. 
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2.8.E Calculation 
All results were expressed in MFI at fixed dilution (1:10,000). The 
lower limit of quantitation for HlaH35L, EsxAB, FhuD2, and Sur2 were 
respectively 32, 4.56, 5.92, and 6.59 MFI. MFI was then converted in 
relative light units per ml of serum (RLU/ml) using a mouse serum as 
standard.  
 
2.9 Hla neutralization assay 
Ability of Abs elicited by Combo vaccine to inhibit Hla-induced 
hemolysis was evaluated in an in vitro assay. Seven serial two-fold dilutions 
of mouse sera were incubated with 12.5 nM Hla for 30 min at 37°C in 
agitation (350 rpm). Then, erythrocytes derived from de-fibrinated rabbit 
blood (rabbit red blood cells, RRBC) were added and incubation prolonged 
for further 30 min at 37°C. Plates were then centrifuged for 5 min at 1,000 x 
g and the OD540 of supernatants was determined with a SpectraMax® 
340PC384 Absorbance Microplate Reader (Molecular Devices). OD540 of 
supernatants derived from samples incubated with Hla without serum was 
considered as 100% hemolysis. Incubation with 1% Triton X-100 in water 
was used as positive control (maximal hemolysis), while incubation without 
Hla was the negative control. Percent hemolysis was calculated using as 
denominator the OD540 obtained following lysis of RRBC in absence of 
mouse serum. 
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2.10 Spleen processing 
Spleens were harvested from mice 12 days after the immunization 
and placed in 5 ml of cold RPMI 1640 (Gibco) supplemented with 25 mM 
HEPES (Gibco), 2% heat inactivated fetal bovine serum (FBS; low 
endotoxin, HyClone), and 1x penicillin/streptomycin (Pen/Strep; 100x, Gibco) 
in a 15 ml tube. Spleens were dissociated using the pestle of a 5 ml syringe 
through a 70 μM cell strainer placed on top of a 50 ml Falcon tube. Red 
blood cells (RBC) were lysed by incubating the cell pellet with 1 ml of lysis 
buffer (Biolegend) for 3 min on ice. The reaction was stopped by adding 20 
ml of PBS (Gibco) and splenocytes were then suspended in 10 ml of 
complete medium: cold RPMI 1640 (Gibco) supplemented with 25 mM 
HEPES (Gibco), 10% heat inactivated FBS (low endotoxin, HyClone), 1x 
Pen/Strep (100x, Gibco), and 50 µM β-mercaptoetanol (Sigma). Cell 
suspension was filtered on a 70 µm strainer and cell counts determined 
using Vi-CELL XR 2.03 (Beckman Coulter, Inc.). Splenocytes were finally 
suspended at 2 x 107 cells/ml in complete medium and kept on ice until 
plating. 
  
2.11 Intracellular cytokine staining 
Splenocytes were plated at 2 x 106 cells/well in 96-well plates in 
complete medium and stimulated with anti-CD28 and anti-CD49d (2 µg/ml 
each; BD Biosciences) plus the combination of HlaH35L, EsxAB, FhuD2, and 
Sur2 (each 10 μg/ml) (Combo) or with 2 µg/ml Staphylococcus enterotoxin B 
(SEB; Sigma) at 37°C, 5% CO2 for 20-22 h, in the presence of Brefeldin A 
(5 μg/ml) for the last 4 h.  
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Cells were stained with Live/Dead yellow (Invitrogen) diluted 1:1,000 in PBS 
for 20 min at RT, fixed and permeabilized with Cytofix/Cytoperm (BD 
Biosciences) for 20 min on ice, washed in Perm/Wash buffer 1x (BD 
Biosciences), incubated with anti-CD16/CD32   Fc block (BD Biosciences) 
for 20 min at RT, stained with fluorochrome-conjugated monoclonal Abs 
(mAbs) diluted in Perm/Wash buffer 1x (see Table 2.1 for Abs) for 20 min at 
RT, washed twice in Perm/Wash buffer 1x, and finally suspended in PBS. 
Samples were acquired on a LRSII SOS1 flow cytometer (BD Biosciences) 
and analyzed using FlowJo software (TreeStar). 
 
Fluorochrome-conjugated mAbs 
CD3 PerCP-Cy5.5 (BD Pharmingen) 
CD4 V500 (BD Pharmingen) 
CD8 PE-Texas Red (Invitrogen) 
CD44 V450 (BD Pharmingen) 
TCR / PE-Cy5 (eBioscience) 
IL-2 APC (BD Pharmingen) 
TNF Alexa 700 (BD Pharmingen) 
IFN- PE (BD Pharmingen) 
IFN- FITC (BD Pharmingen) 
IL-4 A488 (eBioscience) 
IL-13 A488 (eBioscience) 
IL-17A PE-Cy7 (eBioscience) 
IL-17A A-488 (eBioscience) 
IL-17F A-647 (BD Pharmingen) 
RoRt PE (BD Pharmingen) 
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Table 2.1 (previous page) Fluorochrome-conjugated mAbs used for flow 
cytometry analysis. The appropriate dilution of each fluorochrome-conjugated 
mAb was determined with Ab titration prior to staining. The Abs listed were used in 
3 different staining panels: 
Panel 1: CD3 PerCP-Cy5.5, CD4 V500, CD8 PE-Texas Red, CD44 V450, IL-2 
APC, TNF Alexa 700, IFN- PE, IL-4 A488, IL-13 A488, IL-17A PE-Cy7. 
Panel 2: CD3 PerCP-Cy5.5, CD4 V500, CD8 PE-Texas Red, CD44 V450, TCR / 
PE-Cy5, IFN- PE, IL-17A A-488. 
Panel 3: CD3 PerCP-Cy5.5, CD4 V500, CD8 PE-Texas Red, CD44 V450, TCR / 
PE-Cy5, IFN- FITC, IL-17A PE-Cy7, IL-17F A-647, RoRt PE. 
 
2.12 Cytokine quantification in splenocyte culture 
supernatants 
Splenocytes were plated at 2 x 105 cells/well in 96-well plates in 
complete medium and stimulated with 30 μg/ml ovalbumin (OVA; Hyglos), 
or Combo (10 μg/ml each Ag), or with 2 µg/ml SEB  (Sigma) at 37°C, 5% 
CO2 for 48 h. Plates were then centrifuged at 300 x g for 5 min and 
supernatants were harvested, divided in aliquots, and stored at -20°C until 
analysis.  
Supernatants were analyzed for TNF, IL-2, IFN-, and IL-4 content 
using the MSD 96-Well MULTI-SPOT Mouse Th1/Th2 9-plex Tissue Culture 
kit (Meso Scale Discovery). IL-17A and IL-13 were detected using the MSD 
96-Well MULTI-SPOT Mouse 4-plex custom kit (Meso Scale Discovery). 
Cytokine detection was conducted according to the manufacturer’s 
instructions. In brief, undiluted samples (25 μl) were incubated on 96-well 
plates pre-spotted with capture Abs against the cytokines for 2 h. The 
SULFO-TAG detection Ab solution (25 μl) was added and co-incubated with 
samples on the plate for other 2 h. After washing, MSD Read Buffer T was 
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added and the plate was read immediately on a Sector Imager 6000 (Meso 
Scale Discovery). Data analysis used MSD Discovery Workbench software 
2.0 (Meso Scale Discovery).  
Supernatants were analyzed for IL-17F content using the Bio-Plex 
Pro™ Mouse Cytokine Th17 Panel B 8-Plex (Bio-Rad). Cytokine detection 
was conducted according to the manufacturer’s instructions. In brief, the 
capture Ab-coupled beads were first incubated with Ag standards or 
undiluted supernatants followed by incubation with biotinylated detection 
Abs. After washing away the unbound biotinylated Abs, the beads were 
incubated with a reporter streptavidin-phycoerythrin conjugate (SA-PE). 
Following removal of excess SA-PE, the beads were passed through the 
Bio-Plex 200 array reader (Bio-Rad). Incubations were performed at room 
temperature. All washes were performed using a Bio-Plex® Handheld 
Magnetic Washer (Bio-Rad). Data acquisition was performed using Bio-Plex 
Manager™ software (Bio-Rad) at low PMT setting. 
 
2.13 Cytokine quantification in mouse sera 
Mice were bled 3 h post immunization. Sera were stored at -20°C 
until the day of analysis.  
Samples were analyzed for IL-6 content using the MSD 96-Well 
MULTI-SPOT Mouse Pro-inflammatory 7-plex Tissue Culture kit (Meso 
Scale Discovery). IL-23 was detected in mouse sera using the Bio-Plex 
Pro™ Mouse Cytokine Th17 Panel B 8-Plex (Bio-Rad). TGF-β was 
quantified with the Bio-Plex Pro™ TGF-β 3-plex assay (Bio-Rad). Cytokine 
detection was conducted according to the manufacturer’s instructions. 
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Samples were tested undiluted on the MSD kit, diluted 1:4 in sample diluent 
for IL-13 detection, and diluted 1:16 in sample diluent for TGF-β 
quantification. 
 
2.14 Proliferation assay 
Splenocytes were plated at 1 x 106 cells/well in 96-well plates in 
complete medium and stimulated with 30 μg/ml OVA (Hyglos), or Combo 
(10 μg/ml each Ag), or with 1 μg/ml plate-bound anti-CD3 (BD Biosciences) 
at 37°C, 5% CO2 for 90 h, in the presence of 10 µM 5-ethynyl-2’-
deoxyuridine (EdU; Invitrogen) in complete medium for the last 18 h.  
The cells were then stained with Live/Dead yellow (Invitrogen) for 
20 min at RT, incubated with anti-CD16/CD32 Fc block (BD Biosciences) for 
20 min at RT, and stained with fluorochrome-conjugated mAbs: anti-CD44-
APC (BD Pharmingen), anti-CD4-PB and anti-CD8-PE-Texas Red 
(Invitrogen) diluted in PBS for 20 min at RT. Samples were then fixed with 
Cytofix (BD Biosciences) for 15 min on ice, washed twice with  0.1% BSA in 
PBS, and suspended in 100 µl/well of Click-iT™ EdU reaction cocktail 
(Invitrogen). Cells were incubated 30 min at RT in the dark, washed twice 
with 1x saponin-based permeabilization/wash buffer (Invitrogen), and finally 
suspended in 0.1% BSA in PBS. Samples were acquired on a LRSII SOS1 
flow cytometer (BD Biosciences) and analyzed using FlowJo software 
(TreeStar). 
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2.15 CD4
+
 T-cell depletion 
BALB/c mice were treated i.p. with 100 µg of a rat anti-mouse CD4 
mAb (IgG2b; clone GK1.5; BioXCell) or isotype control (rat IgG2b; BioXCell) 
2 and 4 days before S. aureus infection. The day before infection, mice 
were bled to control the efficacy of the CD4+ T-cell–depleting treatment. For 
this purpose,  blood was diluted 1:4 in PBS (Gibco) and incubated for 10 
min on ice with RBC lysis buffer (Biolegend). Blood cells were then washed 
with PBS and stained with Live/Dead yellow (Invitrogen) diluted 1:1,000 in 
PBS for 20 min at RT. Anti-CD16/CD32 Fc block (BD Biosciences) was 
added for 20 min at RT. CD4+ and CD8+ T cells were identified by staining 
cells with anti-CD3-PerCP-Cy5.5 (BD Pharmingen), anti-CD4-PB, and anti-
CD8-PE-Texas Red (Invitrogen) mAbs for 20 min at RT. The appropriate 
dilution of each fluorochrome-conjugated mAb was determined with Ab 
titration prior to staining.  Cells were washed twice with 0.1% BSA in PBS, 
fixed with Cytofix (BD Biosciences) for 20 min on ice, and washed with 0.1% 
BSA in PBS. Samples were acquired on a LRSII SOS1 flow cytometer (BD 
Biosciences) and analyzed using FlowJo software (TreeStar).  
 
2.16 In vivo cytokine neutralization 
To neutralize IL-17A and/or IFN- in vivo, mice immunized with          
alum/S-7±Combo were treated with 100 µg/mouse of a neutralizing mouse 
anti-mouse IL-17A mAb (IgG1; clone 17F3; BioXCell) and/or a neutralizing 
rat anti-mouse IFN-  mAb (IgG1; clone XMG 1.2; BioXCell) i.p. every other 
day starting from 3 h prior to S. aureus challenge until sacrifice. Control 
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mice received the same amount of isotype-matched control mAbs (mouse 
IgG1 and rat IgG1; BioXCell) or the same volume of PBS (Gibco). 
 
2.17 Statistical analysis 
Mouse survival was analyzed for significance using the log-rank 
(Mantel-Cox) test. The bacterial load following S. aureus infection, 
represented as the log10 CFU/kidneys, was analyzed for statistical 
significance with the unpaired Student’s t test, two-tailed. Quantification of 
mouse peritoneal abscess formation and of Ag-specific Abs was analyzed 
for statistical significance using the unpaired Mann Whitney U-test, two-
tailed. Effective dose 50 (ED50) of Combo-specific Abs able to inhibit       
Hla-induced hemolysis was calculated using a "log(agonist) vs. normalized 
response" nonlinear regression curve. T-cell responses to vaccination were 
analyzed using ANOVA and Tukey’s or Bonferroni’s post-test correction. 
Statistical analyses were performed using GraphPad Prism 5 software 
(GraphPad Software, Inc.). All experiments were examined for 
reproducibility. 
  
 
 
Chapter 3 
Results 
 
3.1 Combo+alum/S-7 protects mice from S. aureus-
induced peritonitis more efficiently than Combo or 
Combo+alum 
To assess whether Combo vaccine adjuvanted with alum/S-7 
afforded greater protection against staphylococcal infection than the vaccine 
either non-adjuvanted or adjuvanted with alum, a head to head comparison 
of the vaccines was performed in the peritonitis model of S. aureus infection. 
Combo Ags, alone or formulated with alum or alum/S-7, were used to 
immunize BALB/c mice i.m., while negative controls received identical 
courses of buffer alone (saline) or adjuvant alone (alum or alum/S-7). On 
day 12 after immunization mice were injected i.p. with a lethal dose of         
S. aureus Newman strain (used throughout all experiments) containing        
5 x 108 CFU. Preliminary titration showed that this dose caused the death of 
approximately 80% of untreated mice (i.e. lethal dose 80, LD80). Survival 
and symptoms of infected animals were monitored for 30 days after 
infection (Figure 3.1 A).  
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As expected, injection of 5 x 108 CFU of S. aureus Newman strain 
caused approximately 78% of infected mice to succumb to infection (22% 
survival in the saline group). Of note, the majority of these animals died 
within 24 h. Combo vaccine without adjuvant conferred no protection in this 
model (9% survival) while Combo adjuvanted with alum or alum/S-7 
protected more than adjuvant alone, 41% (P=0.0002 Combo+alum vs. alum) 
and 75% (P<0.0001 Combo+alum/S-7 vs. alum/S-7), respectively. Most 
importantly, the survival of mice vaccinated with Combo+alum/S-7 was 
significantly higher than that of mice vaccinated with Combo+alum 
(P=0.0058). 
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Figure 3.1 (pages 58-59) Survival, peritoneal abscesses and bacterial load in 
kidneys of BALB/c mice immunized with Combo Ags alone or formulated 
with alum or alum/S-7 and infected intraperitoneally with S. aureus. On day 0, 
5-week-old BALB/c mice (n=32) were immunized i.m. with 10 µg of each Ag alone 
or adsorbed to 2 mg/ml alum±50 µg SMIP-7.10. On day 12, mice were challenged 
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with S. aureus Newman (5 x 108 CFU) i.p. (A) Mice were monitored for survival for 
30 days post challenge. Log-rank (Mantel-Cox) test: survival of Combo+alum/S-7 
immunized mice vs. alum/S-7 immunized mice and of Combo+alum immunized 
mice vs. alum immunized mice, *** P<0.001. Thirty days after S. aureus inoculation, 
mice vaccinated with Combo+alum or Combo+alum/S-7 that survived to infection 
(Combo+alum: n=13; Combo+alum/S-7: n=23) were euthanized, abscesses in the 
peritoneal cavity were enumerated, kidneys were excised and their staphylococcal 
load was determined by plating homogenized tissue on agar plates and 
enumerating the CFU. (B) Number of abscesses in the peritoneal cavity; bars 
represent the median±interquartile range of each group. Mann Whitney U-test, two-
tailed: ** P<0.01. (C) Log10 CFU/kidney; lines and error bars represent the 
mean±SEM. Unpaired t test, two-tailed: ** P<0.01. LLOD=Lower Limit Of Detection. 
(D) Peritoneal cavity of mice belonging to Combo+alum or (E) to Combo+alum/S-7 
groups, respectively.  
 
 
To investigate whether S. aureus was cleared more efficiently upon 
vaccination with Combo+alum/S-7 than with Combo+alum, survivors were 
sacrificed at day 30 after challenge, peritoneal abscesses were enumerated 
by visual inspection and the staphylococcal load in renal tissue was 
determined by counting the CFU in kidney homogenates.  
Peritoneal abscesses were found in mice belonging to both 
vaccination groups (Figure 3.1 B, D, E), however their number was 
significantly lower in the Combo+alum/S-7 group than in the Combo+alum 
group (P<0.01). In addition, not only the size of abscesses was considerably 
smaller (not shown) but also the percentage of mice free of peritoneal 
abscesses was remarkably higher in mice vaccinated with Combo+alum/S-7 
than in mice vaccinated with Combo+alum (50% vs. 31%, Figure 3.1 B). 
In addition, one month after the injection of S. aureus no 
staphylococci were detected in kidneys of 87% of mice immunized with 
Combo+alum/S-7 vs. 54% of mice immunized with Combo+alum (Figure 3.1 
C). 
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Together, these data showed that alum/S-7 is a more efficacious 
adjuvant than alum for Combo vaccine since it conferred not only better 
protection from mortality (75% of survivors vs. 41%) but also promoted a 
more efficient clearance of bacteria not only at the infection site (peritoneum) 
but also at distant organs (e.g., kidney). Remarkably, no signs of infection 
were found at either location in half of the mice vaccinated with 
Combo+alum/S-7.  
 
3.2 Combo+alum/S-7 outperforms Combo or 
Combo+alum at inducing Combo-specific IgG 
The capacity of Combo-based vaccines to induce production of Abs 
specific for each of the vaccine Ags was evaluated by collecting sera 12 and 
32 days after vaccination.  
Twelve days after vaccination, low HlaH35L-specfic IgM titers were 
measured in sera from mice vaccinated with Combo adjuvanted with alum 
or alum/S-7, while titers were below the detection limit for non-adjuvanted 
Combo. Ag-specific IgM titers were below detection limit for EsxAB, FhuD2, 
and Sur2 (data not shown). 
In sera from mice vaccinated with Combo, IgG specific for HlaH35L 
(but not for the other Combo Ags) were detected by day 12 (Figure 3.2). At 
day 32 after vaccination, anti-HlaH35L IgG were significantly increased and 
anti-EsxAB IgG were detected in some mice.  
In sera from mice vaccinated with Combo+alum, IgG specific for HlaH35L, 
EsxAB, and FhuD2 (but not Sur2) were detected by day 12 after vaccination.  
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Figure 3.2 (pages 62-63) Combo-specific IgG in mouse serum 12 or 32 days 
after immunization with Combo alone or formulated with alum or alum/S-7. 
BALB/c mice (32/group from 3 independent experiments) were bled 12 or 32 days 
after vaccination.  Levels of total IgG specific for each Combo Ag were measured 
in sera by Luminex technology and expressed as RLU/ml. Lines and error bars 
represent median±interquartile range. Mann Whitney U-test, two-tailed:                
*** P<0.001 and ** P<0.01. Blue stars indicate differences between 
Combo±saline/adjuvant vs. saline/adjuvant alone. Brown stars indicate differences 
between day 12 and day 32 within the same vaccination group. Black stars indicate 
differences between different vaccination groups at the same time. LLOD=Lower 
Limit Of Detection; LLOQ=Lower Limit Of Quantitation. 
 
 
IgG levels specific for these Ags increased significantly at day 32 after 
vaccination. 
In sera from mice vaccinated with Combo+alum/S-7, IgG specific for each of 
the Combo Ags were detected already by day 12 after vaccination and 
increased significantly at day 32 after vaccination. Remarkably, IgG levels 
specific for each Combo Ag of mice vaccinated with Combo+alum/S-7 were 
always significantly higher than those of mice vaccinated with Combo+alum 
bled at the same time after vaccination.  
Overall, alum/S-7 is a more efficacious adjuvant than alum for 
Combo vaccine since it elicited faster and stronger Combo-specific Ab 
production. 
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3.3 Combo+alum/S-7 induces Hla-neutralizing antibodies 
It has recently been shown that Hla plays a central role in causing 
the death of mice infected i.p. with S. aureus. In addition, Abs against Hla 
are protective in the peritonitis model [155]. Therefore, we decided to test 
whether anti-Hla Abs induced by vaccination with Combo formulated with 
alum/S-7 were not only more abundant but also more effective at 
neutralizing Hla toxic activity than those induced by vaccination with 
Combo+alum.  
For this purpose we performed a Hla hemolytic activity neutralization assay 
[156] in which wild type Hla (12.5 nM), pre-incubated or not with serial 
dilutions of pooled serum from vaccinated mice, was incubated with rabbit 
erythrocytes. Erythrocyte lysis was measured reading the optical density at 
540 nm (OD540), where the emission of hemoglobin can be detected in 
sample supernatants.  
No hemolysis inhibition was detected with pre-immune sera or with 
sera from mice immunized with saline, alum, or  alum/S-7 alone (data not 
shown). At day 12 after vaccination, dose-dependent inhibition of hemolysis 
was observed only in sera from mice vaccinated with Combo+alum/S-7 
while at day 32, Hla neutralizing activity was measured in sera from mice 
vaccinated with Combo, Combo+alum, and Combo+alum/S-7 (Figure 3.3).   
In conclusion, Combo+alum/S-7 vaccine induced stronger and 
faster Hla neutralizing activity than Combo+alum vaccine. 
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Figure 3.3 Hla neutralizing activity of sera from vaccinated mice. Sera from 
mice vaccinated with Combo (green), Combo+alum (blue) or Combo+alum/S-7 
(pink) were collected 12 and 32 days after vaccination. S. aureus α-hemolysin 
(12.5 nM) was pre-incubated for 30 min with serial two-fold dilutions of pooled sera 
(triplicates). Then, RRBC were added and incubation continued for another 30 min. 
Percent hemolysis was calculated reading the OD540 of supernatants and using as 
denominator the OD540 of RRBC incubated with Hla in the absence of mouse 
serum. Dots correspond to the mean of triplicates and bars represent the SEM. 
Data were interpolated and the effective dose that neutralized 50% of Hla activity 
(ED50) was calculated using a "log(agonist) vs. normalized response" nonlinear 
regression curve in GraphPad Prism. Each sample was obtained pooling sera from 
16 mice from one experiment. Data are representative of 2 independent 
experiments. 
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3.4 Antibodies/B cells are needed to achieve protection 
with Combo+alum and Combo+alum/S-7 vaccination  
To establish if Abs induced by vaccination with Combo+alum or 
Combo+alum/S-7 are required to protect mice against peritoneal challenge 
with S. aureus, we used JH mice that are genetically unable to produce Abs. 
JH mice carry a deletion in the JH gene that does not allow B cells to 
produce a recombined version of the variable region of the heavy chain of 
Igs. Therefore, B cell differentiation is blocked at the large, CD43+ precursor 
stage (CD220+CD43+sIg-). No IgM or IgG can be detected in the serum, 
while these mice have apparently normal T-cell development, surface 
phenotype, and numbers in spleen.  
JH mice immunized with Combo, Combo+alum, Combo+alum/S-7, or with 
adjuvants only were infected i.p. 12 days later with 5 x 108 CFU of   S. 
aureus, and their survival was monitored for 10 days after infection. JH mice 
were maintained in a Murine Pathogen Free (MPF) isolated barrier unit.  
As shown in Figure 3.4, 96% of JH mice died within 24 h following 
infection. Only 2 JH mice survived until day 10 after infection: 1 in the group 
immunized with Combo+alum (4%) and 1 in the group immunized with 
Combo+alum/S-7 (4%). (These 2 mice had neither abscesses in the 
peritoneum nor CFU in kidneys suggesting that they might have been not 
infected). 
In parallel experiments, immunization with Combo or Combo+alum 
protected BALB/c mice housed in a MPF isolated barrier unit very poorly    
(8% and 12% survival, respectively) while Combo+alum/S-7 still protected 
88% of BALB/c mice. The increased sensitivity to i.p. infection with              
S. aureus of BALB/c mice housed in MPF conditions (Figure 3.4) vs. 
BALB/c mice housed in non-isolated conditions (Figure 3.1 A) suggested 
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that mice housed in non-MPF conditions may be exposed to and develop 
protective Abs against S. aureus. 
Altogether, these data showed that Abs/B cells are absolutely 
required to mediate protection against an i.p. infection with S. aureus in 
response to vaccination with Combo adjuvanted with alum or alum/S-7. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Survival of immunized BALB/c and JH following lethal challenge 
with S. aureus. BALB/c or JH mice immunized with Combo, Combo+alum, or 
Combo+alum/S-7, or with adjuvant alone were challenged i.p. with S. aureus       
12 days after immunization, and their survival was followed for 10 days. Data were 
pooled from 4 independent experiments (Combo±adjuvant groups: n=25; adjuvant 
groups: n=15). Log-rank (Mantel-Cox) test: survival of Combo+alum/S-7 
immunized BALB/c mice vs. alum/S-7 immunized BALB/c mice, *** P<0.001. 
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3.5 Antibodies induced by Combo+alum/S-7 immunization 
have a protective role against S. aureus-induced 
peritonitis 
We have shown that Combo+alum/S-7 protected mice from            
S. aureus infection more efficiently than Combo or Combo+alum and 
induced higher levels of Combo-specific IgG and Hla-neutralizing Abs. In 
addition, experiments performed in JH mice have shown that Abs and/or      
B cells are required for Combo vaccine-induced protection. Thus, to 
establish more directly the role played by Abs in the protection conferred by 
the Combo+alum/S-7 vaccine, we performed passive transfer experiments 
in which serum from mice vaccinated with Combo+alum/S-7 was injected 
intravenously (i.v.) in naive mice 1 day before infection. As negative control, 
we used serum from mice vaccinated with alum/S-7 alone. Mouse survival 
after infection was followed for 15 days. For comparison, a group of mice 
was vaccinated actively with Combo+alum/S-7. Serum for passive 
immunization experiments was prepared bleeding mice 32 days after active 
immunization since, theoretically, anti-Combo IgG titers achieved by passive 
transfer of 150 µl/mouse should result in IgG titers comparable to those 
induced by active immunization at the time of challenge (12 days post 
vaccination). To control that this was indeed the case, 2 mice/group were 
bled just before infection and anti-Combo IgG measured.  
As shown in Figure 3.5 B, levels of anti-Combo IgG were 
comparable in mice vaccinated either actively or passively. When mice were 
injected with serum derived from Combo+alum/S-7 immunized mice, 28% of 
the animals survived to the lethal challenge for 15 days as compared to 0% 
in the group that received serum from mice immunized with alum/S-7 alone 
(Figure 3.5 C). Of note, all mice were protected up to 4 days post infection 
by passive transfer of serum from Combo+alum/S-7 immunized mice.  
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Figure 3.5 (previous page) Passive transfer of mouse serum from 
Combo+alum/S-7 immunized mice protected mice from lethal challenge with 
S. aureus. (A) Serum from mice immunized with alum/S-7 or Combo+alum/S-7 
was collected 32 days post-vaccination, pooled (36 mice/group), and injected into 
the tail vein of BALB/c mice (150 µl/mouse); 24 h later, animals were infected i.p. 
with S. aureus Newman. (B) Mice from one experiment (n=2) were bled 1 h before 
infection and sera were analyzed for Combo-specific IgG content by Luminex 
technology. (C) Mice were monitored for survival for 15 days post challenge. Data 
were pooled from 2 independent experiments (n=16). Log-rank (Mantel-Cox) Test: 
survival of Combo+alum/S-7 vs. alum/S-7 passively or actively immunized mice,  
*** P<0.00; survival of Combo+alum/S-7 passively vs. actively immunized mice, *** 
P<0.001. 
 
 
These data showed that Combo-specific Abs induced by a single 
immunization with Combo+alum/S-7 could protect mice from a lethal i.p. 
challenge with S. aureus. 
However, passive immunization was not as effective as active 
immunization with Combo+alum/S-7 at protecting mice either from lethal 
challenge 15 days post infection (28% vs. 73% survival, respectively; 
P=0.008) or from bacterial growth in the peritoneum and in kidneys (Figure 
3.6).  
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Figure 3.6 Effect of passive transfer of mouse serum from Combo+alum/S-7 
immunized mice on the number of peritoneal abscesses and bacterial load in 
kidneys of mice following lethal challenge with S. aureus. 150 µl of serum from 
alum/S-7 or Combo+alum/S-7 immunized mice were injected into the tail vein of 
naïve BALB/c mice 1 day prior to i.p. infection with S. aureus Newman. (A) Fifteen 
days after inoculation, animals were euthanized and abscesses in the peritoneal 
cavity were enumerated. Data were pooled from 2 independent experiments 
(Combo+alum/S-7 active immunization: n=11; Combo+alum/S-7 passive 
immunization: n=5). Lines and error bars represent median±interquartile range. 
Mann Whitney U-test, two-tailed. (B) Staphylococcal load in kidneys was 
determined by plating homogenized tissue on agar plates and enumerating CFU. 
Lines and error bars represent mean±SEM. Unpaired Student’s t test, two-tailed. 
 
 
Altogether, these data showed that Combo-specific Abs elicited by 
one immunization with Combo+alum/S-7 play a central role in protection 
against S. aureus in the peritonitis model, and suggested that other immune 
mechanisms could contribute to the very good protection achieved by active 
vaccination with Combo+alum/S-7. 
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3.6 Combo-specific CD4
+
 T cells induced by 
Combo+alum/S-7 immunization do not proliferate in 
vitro 
The relevance of CD4+ T cells in protection against S. aureus 
infections has been suggested by clinical observations as well as by mouse 
studies [157] [158] [159] [160] [161] [162]. Therefore, we decided to 
evaluate the contribution of the T-cell response to the efficacy of Combo 
vaccine adjuvanted with alum/S-7.  
First, we assessed if vaccination induced detectable Combo-specific 
CD4+ T-cell responses by looking at CD4+ T-cell proliferation. For this 
purpose, splenocytes from BALB/c mice vaccinated with Combo, 
Combo+alum, or Combo+alum/S-7 were collected 12 days after 
immunization and stimulated in vitro with or without Combo (10 µg/ml each 
Ag) for 90 h. Click-IT EdU incorporation was measured by flow cytometry, 
as described in paragraph 2.14. 
Proliferation assay showed that Combo-specific CD4+ T cells 
induced by immunization with Combo or Combo+alum were able to 
proliferate after in vitro stimulation, while those induced by immunization 
with Combo+alum/S-7 were not (Figure 3.7). 
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Figure 3.7 Combo-specific CD4+ T-cell proliferation. BALB/c mice were 
immunized with Combo (close green symbol), Combo+alum (close blue symbol), or 
Combo+alum/S-7 (close pink symbol) or, as negative controls, with saline (green 
open symbol), alum (blue open symbol), or alum/S-7 (pink open symbol) only. 
Twelve days after vaccination, mice were sacrificed and splenocytes from each 
mouse were stimulated in vitro with complete medium or Combo  for 96 h. The 
graph shows the numbers of Edu+CD4+CD44high T cells. Lines and error bars 
represent mean±SEM. Data were pooled from 2 independent experiments (n=10). 
ANOVA and Tukey’s post-test correction: * P<0.05 and *** P<0.001. 
 
3.7 Combo+alum/S-7 polarized Combo-specific CD4
+
       
T-cell responses to Th1/Th17 
We have shown that Combo and Combo+alum immunization are 
able to elicit proliferating Combo-specific CD4+ T cells. Therefore, we 
assessed if vaccination induced a detectable Combo-specific CD4+ T-cell 
response by flow cytometry analysis. For this purpose, splenocytes from 
BALB/c mice vaccinated with Combo, Combo+alum, Combo+alum/S-7, or 
adjuvant alone were collected 12 days after immunization and stimulated   
in vitro with or without Combo for 18 h. Brefeldin A was added to the 
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cultures during the last 4 h to block cytokine secretion. Cells were then 
loaded with Live/Dead stain to allow exclusion of dead cells from the 
analysis, fixed, permeabilized to allow staining of intracellular cytokines, and 
stained with fluorescently-labeled mAbs against T-cell markers: CD3, CD4, 
and CD8, the activation marker CD44, and against cytokines: TNF, IL-2, 
IFN-(Th1 signature cytokine), IL-17 (Th17 signature cytokine), IL-4/IL-13 
(Th2 signature cytokines). mAbs anti-IL-4 and anti-IL-13 were labeled with 
the same fluorophore (see panel 1). Cells were analyzed by multiparametric 
flow cytometry according to the gating strategy reported in Figure 3.8. 
 
 
Figure 3.8 (next page) Gating strategy for intracellular cytokine staining 
analysis of CD4+CD44high T cells. Spleen cells from a mouse vaccinated with 
Combo+alum/S-7 stimulated with Combo for  18 h (Brefeldin A was added for the 
last 4 h). Cells were stained with Live/Dead yellow, fixed, permeabilized and 
stained with monoclonal mAbs labeled with different fluorochromes directed 
against CD3, CD4, CD8, CD44, TNF, IL-2, IFN-, IL-17A, IL-4, and IL-13 (same 
fluorochrome anti-IL-4 and anti-IL-13, see  panel 1), and analyzed by 
multiparametric flow cytometry. Live cells were identified based on Live/Dead 
staining. Lymphocytes were identified first based on a morphological gate (forward 
scatter area, FSC-A vs. side scatter area, SSC-A). Single cells were identified 
based on forward scatter properties (side scatter width, SSC-W vs. SSC-A). 
CD4+CD44high T cells were then identified based on expression of CD3, CD4, and 
CD44 markers. Inside the CD4+CD44high T-cell population, cells producing TNF,   
IL-2, IFN-, IL-17A, or IL-4/IL-13 were identified setting gates on non-stimulated 
cells (not shown). Boolean gates were used to identify the total number of cells that 
produced any cytokine in each cell sample. 
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The response of non-stimulated cells was subtracted from that of cells 
stimulated with Combo. Stimulation with an irrelevant Ag, OVA, did not 
increase the percentages of cytokine-producing CD4+CD44high T cells (data 
not shown). Figure 3.8 shows representative flow cytometry dot p lots of 
Th0 
Th1 Th2 Th17 
RESULTS                                                                                                                                 77 
 
spleen cells from a Combo+alum/S-7 vaccinated mouse stimulated with 
Combo.  
 
 
 
 
 
 
 
 
Figure 3.9 Magnitude of Combo-specific CD4+ T-cell responses in mice 
vaccinated with Combo, Combo+alum, or Combo+alum/S-7. BALB/c mice were 
immunized with Combo (close green bar), Combo+alum (close blue bar), or 
Combo+alum/S-7 (close pink bar) or, as negative controls, with saline (green open 
bar), alum (blue open bar), or alum/S-7 (pink open bar) only. Twelve days after 
vaccination, mice were sacrificed and splenocytes from each mouse were 
stimulated or not in vitro with Combo Ags for 18 h. The response of non-stimulated 
cells was subtracted from that of stimulated cells. The graph shows the 
percentages of CD4+CD44high T cells producing any combination of TNF, IL-2,   
IFN-, IL-17A, IL-4, IL-13 (panel 1) in response to Combo stimulation. Bars 
represent mean±SEM (n=16 from 3 independent experiments). ANOVA and 
Tukey’s post-test correction: ** P<0.01 and  *** P<0.001. 
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with either Combo+alum or Combo+alum/S-7 induced statistically 
significantly higher percentages of cytokine-producing CD4+CD44high T cells 
as compared to vaccination with alum or alum/S-7 only. The magnitude of 
the CD4+ T-cell response of mice immunized with Combo+alum/S-7 was 
higher compared to that of mice vaccinated with Combo or Combo+alum 
(Figure 3.9). 
Then, we proceeded to analyze the quality of cytokines produced by 
Combo-specific CD4+ T cells from mice vaccinated with Combo+alum or 
Combo+alum-S-7. We found comparable percentages of Combo-specific  
IL-2–producing CD4+CD44high T cells in mice vaccinated with Combo+alum 
or Combo+alum/S-7, while higher percentages of TNF-producing cells were 
found in the Combo+alum/S-7 group. On the contrary, higher percentages 
of IL-4/IL-13–producing cells were found in the Combo+alum group. In 
addition, much higher percentages of IFN-–producing cells were found in 
the Combo+alum/S-7 vs. Combo+alum group, while low percentages of    
IL-17A–producing cells were found in the Combo+alum/S-7 group only 
(Figure 3.10).  
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Figure 3.10 Quality of Combo-specific CD4+ T-cell responses in mice 
vaccinated with Combo+alum or Combo+alum/S-7. BALB/c mice were 
immunized with Combo+alum (close blue bar) or Combo+alum/S-7 (close pink bar) 
or, as negative controls, with alum (blue open bar) or alum/S-7 (pink open bar) only. 
Twelve days after vaccination, mice were sacrificed and splenocytes from each 
mouse were stimulated or not in vitro with Combo for 18 h. The response of non-
stimulated cells was subtracted from that of stimulated cells. The graphs show the 
percentages of CD4+CD44high T cells producing TNF, IL-2, IFN-, IL-17A, IL-4/IL-13 
in response to Combo stimulation. Bars represent mean±SEM (n=16 from              
3 independent experiments). ANOVA and Tukey’s post-test correction: *** P<0.001, 
** P<0.01, and * P<0.05.  
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Cytokines were measured also in culture supernatants of 
splenocytes stimulated or not with Combo. As shown in Figure 3.11, this 
analysis confirmed that more IFN- and IL-17A were produced by cells from 
mice immunized with Combo+alum/S-7 than from mice immunized with 
Combo+alum.  Comparable IL-2 and IL-4 and higher TNF (not shown) 
production were also observed in mice immunized with Combo+alum/S-7 vs. 
Combo+alum, in agreement with results obtained by intracellular cytokine 
staining. The average concentration of cytokines in non-stimulated cell 
culture supernatants was: 7078.1±7586.8 pg/ml for IL -2, 125.5±135.3 pg/ml 
for IL-4, 5.2±11.5 pg/ml for IL-13, 0.6±1.1 pg/ml for IFN- and 12.6±8.2 
pg/ml for IL-17A. 
Overall, Combo+alum/S-7 vaccine induced higher frequencies of 
Combo-specific CD4+ T cells as compared to Combo+alum vaccine, and 
these T cells were polarized towards Th1 and Th17. 
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Figure 3.11 Cytokines secreted by splenocytes from mice vaccinated with 
Combo+alum or Combo+alum/S-7. Splenocytes were stimulated or not for 48 h 
with Combo. Supernatants were harvested and stored at -20° C until tested. 
Cytokine concentration was measured by MSD kit. The response of non-stimulated 
cells was subtracted from that of cells stimulated with Combo. Bar represent 
mean±SEM (n=6). Data are representative of 3 independent experiments. ANOVA 
and Tukey’s post-test correction: ** P<0.01 and * P<0.05. 
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3.8 Combo-specific IFN-–producing CD4+ T cells induced 
by Combo+alum/S-7 immunization do not produce    
IL-17A or IL-17F and are RORt
-
 
Th17 cells have considerable plasticity in vitro and in vivo and can 
readily acquire the ability to produce IFN- in addition to or instead of IL-17 
production [163] [164] [60] [61] [165]. The developmental plasticity of Th17 
cells toward a Th1-like phenotype (Th1/Th17 that produce both IL-17 and 
IFN-, and ex-Th17 that produce IFN- only) has been well documented in 
models of autoimmune diseases [166].  
Therefore, in the attempt to establish if Combo+alum/S-7 vaccination 
induced these Th1-like cells, we stained cells from mice vaccinated with 
Combo+alum/S-7 for IL-17A, IL-17F, IFN-, and RORt, a lineage-specific 
master regulator of Th17 development that induces the transcription of the 
genes encoding IL-17A and IL-17F. 
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F 
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Figure 3.12 (previous page) Intracellular staining of IL-17A, IL-17F, IFN-, and 
RORt in Combo-specific Th17 cells induced by immunization with 
Combo+alum/S-7. BALB/c mice (n=5) were immunized with Combo+alum/S-7 or 
alum/S-7 alone. Twelve days after vaccination, splenocytes were prepared from 
each mouse and stimulated in vitro with medium or Combo. Splenocytes were 
stained with Live/Dead yellow, fixed, permeabilized, and stained with mAbs 
directed against CD3, CD4, CD8, CD44, IFN-, IL-17A, IL-17F, and RORt (panel 
3). Live cells were identified based on Live/Dead staining. Lymphocytes were 
identified first based on a morphological gate. Single cells were identified based on 
forward scatter properties. CD4+CD44high T cells were then identified based on 
expression of CD3, CD4, and CD44 markers. Within the CD4+CD44high T-cell 
population, cells producing IL-17A, IL-17F, and IFN- were identified. RORt 
expression was evaluated in IFN-–, IL-17A–, and IL-17F–producing cells. 
 
 
As shown in Figure 3.12, Combo-specific CD4+CD44high T cells 
induced by vaccination with Combo+alum/S-7 that produced both IL-17A 
and IFN- were extremely rare (B) and no cells that produced both IL-17F 
and IFN- were found (C). On the opposite, Combo-specific CD4+CD44high  
T cells that produced both IL-17A and IL-17F were observed (A). In addition, 
Combo-specific IFN-+ CD4+CD44high T cells induced upon immunization 
with Combo+alum/S-7 were ROR t- as compared to IL-17A+ or IL-17F+ 
CD4+CD44high T cells that were RORt+ (D vs. E and F), suggesting that they 
were bona fide Th1 cells and not Th1/Th17.  
 
 
 
84                                                                                                                            CHAPTER 3 
 
3.9 Th17-promoting cytokines were found in sera of mice 
vaccinated with Combo+alum/S-7 
Th17 differentiation and expansion have been shown to be 
promoted by TGF-β, IL-6, and IL-23 in mice [42] [43]. Therefore, mice were 
bled 3 h after vaccination with Combo+alum/S-7 or Combo+alum to assess 
whether Th17-promoting cytokines could be found in the serum. 
As shown in Figure 3.13, higher levels of IL-6 and IL-23, and 
comparable levels of active TGF- were found in sera from mice vaccinated 
with Combo+alum/S-7 compared to mice vaccinated with Combo+alum.  
Overall, these data indicated that Combo+alum/S-7 vaccination 
elicits a Th17-promoting cytokine environment. 
 
 
Figure 3.13 (next page) Th17-promoting cytokines in mouse serum after 
vaccination with Combo+alum or Combo+alum/S-7. BALB/c mice were bled 3 h 
after vaccination with Combo+alum or Combo+alum/S-7. (A) IL-6, (B) IL-23p19, 
and (C) TGF- concentrations in serum samples were determined using Bio-Plex 
Pro or MSD kits. Four independent experiments were performed. Sera from the 
same immunization group of each experiment were analyzed in pool (n=12/pool, 4 
pools). Each dot represents a pool, mean±SEM are also shown. ANOVA and 
Bonferroni post-test correction: ** P<0.01 and * P<0.05. 
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3.10 Combo+alum/S-7 vaccination does not induce           
IL-17–producing    T cells 
Recently it has been found that various “innate” subsets of lymphoid 
cells, like   T cells, NK cells, NKT cells, and innate lymphoid cells (ILCs), 
can produce IL-17 [167] [168] [169] [170]. In particular,  T cells can 
produce high amounts of IL-17 [171] in response to IL-23 in combination 
with IL-1β or IL-18, but largely independently of T-cell receptor activation 
[172]. Since we have shown that alum/S-7 immunization induces IL-23 and 
also some IL-1β (data not shown) production, we investigated whether 
immunization with Combo+alum/S-7 promoted IL-17 secretion by  T cells.  
For this purpose, splenocytes were prepared from mice vaccinated with 
Combo alone or formulated with alum or alum/S-7 or, as negative controls, 
with adjuvant alone, 12 days after immunization. Splenocytes, stimulated or 
not in vitro with Combo, were analyzed by intracellular flow cytometry 
following the gating strategy reported in Figure 3.14. 
As shown in Figure 3.15, there was no difference in the mean 
percentage of IL-17–producing TCR+ T cells between any groups despite 
the stimulation with Combo, in line with the fact that IL-17 production by     
 T cells was Ag-independent. The average frequency of  T cells was 0.3% 
of CD3+ cells: 5% of them produced IL-17A and 9% produced IL-17F with or 
without Combo stimulation. 
These data demonstrated that although IL-17–producing  T cells 
were found, they were not induced by vaccination with Combo+alum or 
Combo+alum/S-7. In addition, these cells produced IL-17 independently of 
Ag recognition.  
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Figure 3.14 Gating strategy for intracellular cytokine staining analysis of      
  T cells. Splenocytes were stained with Live/Dead yellow and mAbs directed 
against CD3, TCR, IFN-, IL-17A, IL-17F, and RORt (panel 2). Live cells were 
identified based on the viability marker, lymphocytes were then identified using 
forward scatter and side scatter, and singlets were identified using forward scatter 
properties. Then,  T cells were positively identified as CD3+TCR+ cells. Within 
the  T-cell population, cells producing IFN-, IL-17A, or IL-17F were identified.  
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Figure 3.15 IL-17–producing   T cells in splenocytes of mice vaccinated with 
Combo+alum or Combo+alum/S-7. BALB/c mice were immunized with Combo 
(close green symbol), Combo+alum (close blue symbol), or Combo+alum/S-7 
(close pink symbol) or, as negative controls, with alum (blue open symbol) or 
alum/S-7 (pink open symbol) only. Twelve days after vaccination, mice were 
sacrificed and splenocytes from each mouse were stimulated or not in vitro with 
Combo for 18 h. Frequencies of TCR+ T cells producing (A) IL-17A and             
(B) IL-17F. Lines and error bars represent the mean±SEM (n=5). Data are 
representative of 5 independent experiments. ANOVA and Tukey’s post-test. 
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3.11 Combo-specific CD4
+
 T cells have a protective role 
against S. aureus-induced peritonitis 
We have shown that Combo+alum/S-7 vaccine induced stronger 
Combo-specific CD4+ T-cell responses as compared to Combo+alum 
vaccine, and that the CD4+ T-cell responses were polarized towards Th1 
and Th17.  Therefore, we further asked whether these CD4+ effector T cells 
played a role in protection against S. aureus-induced peritonitis. To address 
this question, we depleted CD4+ effector T cells by injecting an anti-CD4 
mAb at day 6 and 8 after vaccination with Combo+alum/S-7 or, as control, 
with alum/S-7 alone. At day 9 after vaccination, mice were bled to confirm 
that CD4+ T cells were depleted efficiently and that anti-Combo Ab titers in 
sera of mice depleted of CD4+ T cells were not affected (data not shown). 
The day after, mice were challenged with S. aureus and their survival was 
monitored for the following 15 days. To control that the effect of anti-CD4 
mAb was specific, control groups of vaccinated mice were injected with an 
isotype-matched irrelevant mAb (Figure 3.16 A). 
 
 
Figure 3.16 (next page) Effect on survival of CD4+ effector T-cell depletion in 
mice vaccinated with Combo+alum/S-7. (A) On day 6 and 8 after              
alum/S-7±Combo immunization, 100 µg of anti-CD4 or isotype-matched control 
mAb were injected in the peritoneum of BALB/c mice. On day 9, mice were bled 
and the percentage of circulating CD4+ T cells (relative to total CD3+ T cells) was 
determined by flow cytometry analysis. Results from one representative experiment 
are shown. On day 10, mice were infected i.p. with S. aureus and (B) survival was 
monitored for 15 days after challenge. Data were pooled from 4 independent 
experiments (n=48). Log-rank (Mantel-Cox) test:  
Combo+alum/S-7 + anti-CD4 vs. Combo+alum/S-7 + isotype control, * P<0.05. 
Combo+alum/S-7 + isotype control vs. alum/S-7 + isotype control, *** P<0.001.  
Combo+alum/S-7 + anti-CD4 vs. alum/S-7 + anti-CD4 mAb, *** P<0.001. 
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As shown in Figure 3.16 B, treatment with anti-CD4 mAb resulted in 
decreased survival of Combo+alum/S-7 immunized mice compared to 
treatment with isotype control mAb (P=0.0339). Treatment with isotype 
control mAb had no effect on survival of mice vaccinated with 
Combo+alum/S-7 (not shown). 
Mice that survived the infection were subjected to necropsy 15 days 
after challenge. S. aureus bacterial load in kidneys was determined by 
plating homogenized tissue on agar plates and enumerating the CFU.  
As shown in Figure 3.17, mice depleted of CD4+ effector T cells that 
survived the infection had higher bacterial load in kidneys compared to mice 
that received the isotype control mAb, although the differences were not 
statistically significant. 
 
 
 
 
 
 
 
 
 
 
Figure 3.17 Effect of CD4+ effector T-cell depletion on bacterial load in 
kidneys of mice vaccinated with Combo+alum/S-7. BALB/c mice were 
immunized with Combo+alum/S-7 and treated with depleting anti-CD4 (pink symbol) 
or isotype control (blue symbol) mAb prior to challenge with S. aureus. Fifteen days 
after S. aureus inoculation, animals were euthanized and bacterial load in kidneys 
was determined by plating homogenized tissue on agar plates and enumerating 
the CFU. Lines and error bars represent mean±SEM (Combo+alum/S-7 + isotype: 
n=12; Combo+alum/S-7 + anti-CD4: n=7). Data are representative of 4 
independent experiments. Unpaired t test, two-tailed.  
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These data showed that CD4+ effector T cells contribute to the 
protection conferred by Combo+alum/S-7 vaccine. 
 
3.12 in vivo IL-17A neutralization increased the bacterial 
load in kidneys of Combo+alum/S-7 immunized mice  
We demonstrated that Combo+alum/S-7 vaccine induced Combo-
specific IL-17– and IFN-–producing CD4+ T cells and that CD4+ effector T 
cells contributed to the protection conferred by this vaccine. To assess the 
role of IL-17 and/or IFN-, IL-17A and/or IFN-  were neutralized in vivo in 
vaccinated mice prior to infection with S. aureus. 
 
 
 
 
 
 
 
 
 
Figure 3.18 Experimental design of IL-17A and/or IFN- in vivo neutralization. 
BALB/c mice were treated with IL-17A– and/or IFN-–neutralizing or isotype-
matched control mAb 3 h prior to infection with S. aureus, while control animals 
were injected with PBS. Mice were treated with mAb every other day for 15 days 
after infection. 
Immunization: 
BALB/c were 
immunized i.m. with 
alum/S-7±Combo 
IL-17A and/or IFN-γ 
neutralization:    
BALB/c received  
100 µg of IL-17A– 
and/or IFN-γ–
neutralizing or 
isotype ctr mAb i.p.  
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injection, BALB/c 
mice were infected 
i.p. with S. aureus. 
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IFN-γ–neutralizing or 
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every other day after 
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Figure 3.19 (previous page) Effect of in vivo neutralization of IL-17A and/or 
IFN-on survival and bacterial load in kidneys of mice vaccinated with 
Combo+alum/S-7. Survival of BALB/c mice (n=8) immunized with                
alum/S-7±Combo and treated with IL-17A– and/or IFN-–neutralizing mAb or 
isotype-matched control mAb was monitored for 15 days after S. aureus challenge. 
(A) Survival of alum/S-7±Combo immunized mice injected with IL-17A mAb vs. 
isotype control mAb. Log-rank (Mantel-Cox) test: Combo+alum/S-7 + isotype 
control vs. alum/S-7 + isotype control, *** P<0.001. Combo+alum/S-7 + anti-IL-17A 
vs. alum/S-7 + anti-IL-17A, *** P<0.001. (B-D) Fifteen days after S. aureus 
challenge, survivors were euthanized and bacterial load in kidneys was determined 
by plating homogenized tissue on agar plates and enumerating the CFU. Lines and 
error bars represent mean±SEM. Data are representative of 2 independent 
experiments. Unpaired t test, two-tailed: *** P<0.001, and * P<0.05. 
 
 
BALB/c mice immunized with alum/S-7±Combo were injected i.p. with     
100 µg of IL-17A– and/or IFN-–neutralizing or isotype-matched control 
mAb, every other day starting 3 h before infection. Mouse survival was 
monitored for 15 days after bacterial challenge. 
 As shown in Figure 3.19A, treatment of mice immunized with 
Combo+alum/S-7 with neutralizing mAb specific for IL-17A had no effect on 
survival compared to treatment with isotype-matched control mAb. No effect 
on survival was observed either when mice were treated with IFN-–specific 
neutralizing mAb alone or in combination with IL-17A–specific mAb (data 
not shown). Treatment with isotype control mAb had no effect on survival of 
mice vaccinated with Combo+alum/S-7. 
However, in vivo neutralization of IL-17A alone (Figure 3.19 B) or 
together with IFN-  (D), but not of IFN- alone (C), caused an increase in 
bacterial load in kidneys of mice that survived the infection compared to 
survivors injected with isotype control mAb.  
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Moreover, histopathologic analysis of kidneys from mice treated with IL-17A 
mAb showed an increased pathology compared to kidneys from mice 
injected with isotype control mAb (Figure 3.20 B and C vs. A). Kidneys from 
mice treated with IL-17A mAb showed pyelonephritis, characterized by 
abscesses in the interstitium of renal parenchyma, damaged tubules, and 
severe unilateral necrosis.  
 
 
 
 
 
 
 
 
Figure 3.20 Effect of in vivo neutralization of IL-17Aon kidney histopathology 
of mice vaccinated with Combo+alum/S-7 after challenge with S. aureus. 
Combo+alum/S-7 immunized BALB/c mice were infected with S. aureus. After     
15 days, animals were euthanized and the kidneys were excised, fixed in 4% 
buffered formaldehyde, and processed for paraffin embedding. Kidneys were thin 
sectioned, stained with hematoxylin and eosin, and analyzed for histopathology. 
Representative specimens of hematoxylin and eosin-stained kidney of a 
Combo+alum/S-7 immunized mouse treated with (A) isotype control mAb or (B-C) 
IL-17A–neutralizing mAb are shown. 
 
 
 
 
A B 
C 
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Overall, these data indicated that IL-17A induced upon vaccination 
with Combo+alum/S-7 is important to control S. aureus growth and/or 
spreading to distant organs. 
 
  
 
 
Chapter 4 
Discussion 
 
Staphylococcal disease represents a universal burden including 
acute, life-threatening infections as well as chronic infections usually 
associated with foreign materials (e.g., prosthetic devices or catheters), 
often hospital acquired [173]. 
Although it has been extensively investigated, natural protective 
immunity against S. aureus is poorly understood. Acute infection with          
S. aureus does not prevent re-infection [174]. Preclinical and clinical data 
indicate that immunization with intact bacteria induces high serum Ab 
immune titers to Staphylococcus, but does not confer protection against      
S. aureus infection [174] [117].  
To date, both active and passive immunization strategies against    
S. aureus have fai led. Failures in vaccine clinical trials might be due to a 
focus on single targets while S. aureus has a plethora of pathogenic 
mechanisms. In addition, the lack of known correlates of protection in 
humans has severely limited the ability to interpret both preclinical and 
clinical data. Finally, the vaccines tested in humans so far lacked new 
generation adjuvants, which may be critical in augmenting Ab production 
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and steering the T-cell responses toward the proper profile of cytokine 
production [126]. 
In the attempt to overcome these limitations, Novartis Vaccines has 
developed a Combo vaccine against S. aureus consisting of four bacterial 
proteins: HlaH35L, a non-toxic mutant of-toxin [73], EsxAB, which is a 
fusion of EsxA and EsxB secreted virulence factors [128], FhuD2, a surface 
protein involved in iron uptake [129], and Sur2, an internally discovered 
surface protein whose function is currently investigated.  
Recent work has shown that Combo vaccine adjuvanted with alum 
was more protective than single Ags in the peritonitis, kidney abscess, 
pneumonia, and skin mouse infection models (Bagnoli  et al., manuscript in 
preparation). In addition, Combo vaccine conferred a broader protection 
against different staphylococcal strains than single Ags in mice. Combo 
vaccine with or without alum has proven to be safe in a recent phase I 
human clinical trial.  
The aim of the work described in this thesis was to evaluate if the 
inclusion of a novel adjuvant, alum/S-7, which consists of a small molecule 
TLR7a adsorbed to alum, improves the protective efficacy of the Combo 
vaccine in the mouse peritonitis model and to elucidate the underlying 
immunological mechanisms of protection.  
A single dose of Combo+alum/S-7 significantly increased the 
percentage of mice that survived to a lethal challenge with S. aureus 
compared to Combo+alum (Figure 3.1A). Of note, Combo+alum/S-7 not 
only protected the majority of mice from early death caused by S. aureus, 
but also induced sterile immunity in 56% of mice vaccinated with 
Combo+alum/S-7 vs. 31% of mice vaccinated with Combo+alum (Figure 
3.1B-C). This result was very important since Rauch et al. have recently 
reported that Hla is a key determinant of early lethal outcomes associated 
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with i.p. S. aureus challenge. Indeed, infection with hlako mutant bacteria 
caused fewer lethal events, especially within the first 24 h post infection. In 
addition, vaccination with non-toxigenic HlaH35L, which is one component of 
Combo vaccine, or treatment with an Hla-neutralizing mAb protected 
BALB/c mice from death [175]. Nevertheless, mice either infected with hlako 
bacteria or vaccinated with HlaH35L or treated with anti-Hla mAb before 
challenge with wild-type S. aureus presented peritoneal abscess lesions 
that persisted for 15 days after infection, similar to animals that had been 
infected with wild-type S. aureus strains. Further, bacterial load within renal 
abscess lesions was similar for mice infected i.v. with wild-type or hlako 
strains suggesting that once bacteria have been encapsulated in abscesses 
they are no longer attacked by anti-Hla Abs. The authors speculated that 
peritoneal lesions may rupture over time giving rise to new lesions, as 
observed during human peritonitis and peritoneal abscesses. So, the 
eradication of S. aureus from the peritoneum is likely to be very important 
for patients that experience intraperitoneal abscess formation as a 
consequence of continuous peritoneal dialysis for end-stage renal disease 
[176]. In addition, the capability of the immune system to effectively attack  
S. aureus also once it hides inside an abscess is likely to have an impact in 
many other S. aureus-induced pathologies. 
To elucidate the protective mechanisms of Combo+alum/S-7 
vaccine, first we characterized Combo-specific Ab responses. 
Combo+alum/S-7 induced faster and higher Combo-specific Ab titers, and 
Hla-neutralizing activity compared to Combo±alum. IgG responses against 
each of the Combo Ags was detected in mice vaccinated with 
Combo+alum/S-7 by 12 days and increased at day 32 after immunization, 
as did Hla-neutralizing activity (Figure 3.2 and Figure 3.3). 
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The requirement of B cells/Abs to confer protection against             
S. aureus in the peritonitis model by Combo vaccination was evidenced by 
the death of 96% of B-cell ko JH mice vaccinated with Combo+alum/S-7 or 
Combo+alum (Figure 3.4). 
The protective role of Abs induced by Combo+alum/S-7 vaccination 
was confirmed by passive immunization experiments, in which serum from 
actively immunized mice was given to naïve mice before i.p. challenge with 
S. aureus. While 100% of mice passively immunized with Combo+alum/S-7 
serum were live 4 days after challenge, only 6% of mice passively 
immunized with alum/S-7 serum survived at that time. However, passively 
vaccinated mice then started to die and mice that survived for the 15 day 
observation time showed increased peritoneal abscesses and bacterial load 
in kidneys compared to actively vaccinated mice (Figure 3.5 and 3.6). This 
suggested that either Abs induced by active vaccination were not the only 
mechanism involved in protection of mice from death and from bacterial 
spreading or levels of Abs reached with passive transfer declined over the 
15 day observation time. Indeed, preliminary data showed that Combo-
specific Ab titers were lower in mice that survived S. aureus challenge in the 
passively vaccinated group vs. mice actively vaccinated (data not shown) 
suggesting that Ab titers might have become limiting at later times in our 
passive transfer experiments. Since the half-lives of serum Igs in mice are  
2 days for IgM, 4-6 days for IgG2b, and 6-8 days for IgG1, IgG2a and IgG3 
[177], the observed decrease in protection during the 15 day observation 
period after bacterial challenge could mirror this reduction. Further 
experiments are planned to address this point.  
Another aspect that deserves further investigation is that vaccination with 
Combo+alum/S-7, but not with Combo±alum, induced Combo-specific Abs 
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of the IgG2a and IgG2b isotypes (data not shown). These Abs might be 
functionally more efficient at fighting against S. aureus. 
Since several lines of evidence support a role for CD4+ T-cell 
responses to S. aureus infection in mice [123], we studied the role of these 
cells in the protection conferred by Combo vaccine adjuvanted with   
alum/S-7. 
First of all, we showed that vaccination with Combo+alum/S-7 or 
Combo+alum induced measurable Combo-specific CD4+ T-cell responses. 
In particular we observed that one vaccination with Combo+alum/S-7 
induced an increase in frequency of cytokine-producing (Figure 3.9), but not 
proliferating (Figure 3.7) Combo-specific CD4+ T cells as compared to 
Combo+alum vaccination. In addition, Combo+alum/S-7 skewed the T-cell 
responses towards Th1 and Th17 (Figure 3.10) suggesting that a CD4+     
T-cell effector response was induced. The importance of this CD4+ T-cell 
responses for the protection conferred by vaccination with Combo+alum/S-7 
was shown by CD4+ effector T-cell depletion experiments that indicated a 
role for these cells both in survival (Figure 3.16) and bacterial control 
(Figure 3.17). Such a fast and strong CD4+ effector T-cell response might 
be desirable in patients that are scheduled for cardiothoracic surgery since 
S. aureus causes substantial morbidity and mortality following median 
sternotomy [178].  
A recent Phase IIB/III study of V710, a vaccine made of non 
adjuvanted IsdB, did not induce protection against post-surgery bacteremia 
or deep sternal wound infection even if an increase in anti-IsdB IgG levels 
from baseline to day of hospital admission (14-60 days after vaccination) 
was observed. CD4+ T-cell responses were not reported [179]. IsdB has 
been shown to be a potential vaccine candidate for the prevention of           
S. aureus infection in mouse challenge models. Importantly, enhanced 
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protection from lethal i.v. infection was mediated by both IsdB-specific Th17 
cells and IsdB-specific mAb [180].  An observed rise in anti-IsdB titers 
induced by IsdB formulated on aluminum adjuvant correlated with protection 
against lethal S. aureus challenge, indicating that Ab titers may be used as 
a nominal biomarker for vaccine efficacy [99]. However, the negative results 
of the efficacy trial strongly suggest that Abs might not be sufficient and that 
Th17 cells may be important.  
There are other several observations that imply that Abs may not be 
sufficient for protection against S. aureus infection. For example, Abs 
targeted to several S. aureus surface Ags have demonstrated preclinical 
efficacy, including polyclonal anti-capsule type 8 and type 5 [150] [181]  
[182], and Fab to an ABC transporter [183]. However, human clinical trials 
resulted in a disappointing lack of statistically significant efficacy [184] [185] 
[186]. 
In vivo neutralization of IL-17 and/or IFN- in Combo+alum/S-7 
immunized mice showed that while these cytokines, either alone or together, 
had no effect on survival of vaccinated mice, neutralization of IL-17, but not 
of IFN-, caused an increase in bacterial burden in kidneys of vaccinated 
mice (Figure 3.19). These results indicate a role of Combo+alum/S-7 
vaccine-induced Th17 cells in local but not systemic bacterial control. 
Indeed, Th17 cells are essential for intact mucoepithelial host defense 
against S. aureus both in mice and men. For example, double il17a-/- il17f-/- 
mice showed increased susceptibility to mucocutaneous S. aureus abscess 
formation but not to death induced by i.v. S. aureus infection [86]. Similarly, 
patients with hyper-IgE syndrome, despite their systemic Th17 deficiency, 
are prone to staphylococcal skin and lung abscesses but not to S. aureus 
bacteremia. This might be due to differences in site-specific requirements 
for production of antimicrobial peptides and neutrophil chemoattractants [96].  
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Of note, our IL-17 neutralization experiments are likely to have 
underestimated the role of IL-17 since IL-17A, but not IL-17F, which is also 
produced by Combo-specific Th17 cells (Figure 3.12), was neutralized. An 
essential role of IL-17F for S. aureus control was shown by the observation 
that both il-17a and il-17f gene had to be knocked out to lose control of        
S. aureus [86]. Moreover, IL-17F modest signaling activity may be increased 
by TNF, which is induced by Combo+alum/S-7 vaccination (Figure 3.10).  
TNF exhibits potent synergy also with IL-17A and IL-17A/F, probably 
through cooperative enhancement of mRNA stability of certain IL-17 target 
genes [84] [88].  
Local IL-17 production could be part of a protective early immune response 
to peritoneal dialysis-related peritonitis since high levels of IL-17 in 
peritoneal dialysis effluents during the early phase of peritonitis correlated 
with a favorable outcome [187] [86]. Indeed, mesothelial cells, which are 
present in the peritoneum, express IL-17RA [188]. 
IL-17 induces the differentiation of progenitor cells into neutrophils through 
the regulation of G-CSF in bone marrow stromal cells [189], as well as 
neutrophil recruitment, via the regulation of CXC chemokines in epithelial 
cells [190]. IL-17 induces also the production of antimicrobial peptides by 
epithelial cells [57]. This cooperative induction of neutrophil recruitment and 
antimicrobial peptide production increases epithelial barrier function and is 
critical for host defense against S. aureus [191].  
Phagocyte-mediated killing is a crucial defense mechanism against 
S. aureus. Neutrophils not only represent 60% of the leukocyte population in 
the blood and are the most important phagocytic cells, but they are the only 
cells in the immune system that effectively ki ll staphylococci [192]. In 
addition, the speed of neutrophil recruitment is an important factor [193]. 
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Interestingly, IL-17A was shown to recruit neutrophils in the peritoneum of 
mice with zymosan-induced peritonitis [194]. 
In vitro experiments by Frodermann et al. [195] indicated that TLR2 
signaling triggered by S. aureus PGN led to predominantly modulatory or 
pro-inflammatory responses depending on the involvement of Mo/M or DC, 
respectively. As a result of the different imprinting by APC (Mo/M vs. DC), 
the subsequent adaptive response was either an IL-10 response or a 
Th1/Th17 response. S. aureus colonization, primarily occurring in the upper 
respiratory tract, will be facilitated by the predominant presence of Mo/M in 
the submucosa. As a consequence, the vast majority of individuals is 
expected to develop an IL-10 response towards S. aureus infection resulting 
in inefficient bacterial clearance. On the other hand , our Combo+alum/S-7 
vaccine induces a protective Th1/Th17 response. 
It is becoming apparent that adaptive immunity to S. aureus may 
extend beyond neutralizing, opsonizing, and/or complement-fixing Ab 
responses. Vaccines that drive an appropriate cell-mediated immune 
response, including Th17 and/or Th1/Th17 cells, may also contribute to 
acquired protective immunity [196]. Combo vaccine adjuvanted with  
alum/S-7 induces both humoral and cellular immune responses, which may 
both improve efficient eradication of bacterial infection.  
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